Study of the interactions of surface-modified particles with membrane model systems by Sirage, Melissa Margarete Jessen
 UNIVERSIDADE DE LISBOA 
FACULDADE DE CIÊNCIAS 
     Departamento de Física 
 
 
 
 
 
 
 
Study of the Interactions of Surface-Modified Particles with 
Membrane Model Systems 
 
 
 
Mestrado Integrado em Engenharia Biomédica e Biofísica 
 Perfil em Engenharia Clínica e Instrumentação Médica 
 
 
 
 
Melissa Margarete Jessen Sirage 
 
Dissertação orientada por: 
Professor Doutor Hugo Alexandre Ferreira 
Doutora Liana C. Silva 
 
 
2016 
 i 
 
Acknowledgements 
 
The realization of this master thesis was only possible under strong teamwork and individual 
dedication. At the end of this journey, there are some people I want to express my gratefulness.  
 First of all, I want to thank to Professor Hugo Alexandre Ferreira his supervision and support.  
 A great thank to my supervisor Doctor Liana C. Silva for all the support and supervision. Her 
precious meetings of discussion of results and all exigencies during the writing of this master thesis 
was of extreme importance. 
 Thanks to Professor Helena Florindo for accepting me in IntraCell_ADD group. Thanks for all the 
advices and supervision on the work done in microparticles. Thanks also for reviewing my master 
thesis. 
I am grateful to all my colleagues for teaching, advice and guidance during laboratory work. 
Thanks a lot to João Oliveira Conniot, Carina Peres, Joana Silva and Eva Zupančič for accompanying 
me on my first steps on the laboratory formulating microparticles. A very special thanks goes to Ana 
Varela, Ester Ventura, Ana Carreira and also Andreia Giro dos Santos for supporting me during the 
confocal experiments and vesicles’ formulation. Overall, thanks to all my colleagues for making 
IntraCell_ADD a lovely special group to work with! 
 Thanks to Ana Matos for the strong friendship, advices and gaiety. I am very greatful for all your 
advice. 
 A very special thanks to my lovely and exceptional family: parents, brothers, sister and sister in 
law. Thanks for all your unconditional support, all love and for teaching me and inspiring me so much. 
Thank you, thank you, thank you!!! 
An extra special thanks to Fábio Mogas for all love, unconditional support and for helping me 
untangle when all seems complicate. 
 This master thesis marks the end of my Biomedical and Biophysics Engineering course. So I want 
to thank to all my wonderful colleagues from the course that at the same time became friends for live. 
Many thanks to Marina Costa, Neuza Silva, Carolina Vale, Gil Braz, André Girão, Mariana Trincão, 
Tiago João Ferro and Andreia Cândido e Silva. Mainly without all of you, these six years of faculty 
wouldn’t represent Anos Dourados to me. 
 
 
 
 
 ii 
 
Abstract 
 
 The complexity of cell membranes and the development of nano/micro drug delivery systems make 
the topic of interactions between these two structures challenging. Studies point that the surface 
properties of these carriers like size, surface charge, shape and hydrophobicity largely influence such 
interactions. This project aims to study the interactions of surface modified Poly(lactic-co-glycolic 
acid) (PLGA) Microparticles (MPs) with Giant Unilamellar Vesicles (GUVs). 
  MPs were formulated by the double emulsion solvent evaporation method and surface modified 
using chitosan (CH) and alginate (ALG) in order to manipulate the surface charge. Five concentrations 
of coumarin-6 (0.04, 0.10, 0.20, 0.40 and 1.00 g/mg) were entrapped into the PLGA matrix, after 
formulation optimization without probe. Phisichochemical characterization of MPs was made in terms 
of size, surface charge, coumarin-6 loading and morphology. Spectral properties of coumarin-6 were 
analyzed by fluorescence spectroscopy with the five different probe concentrations and five 
concentrations of MPs in suspension (0.10, 0.20, 0.25, 0.40, and 0.50 mg/mL). GUVs with different 
lipid composition and membrane properties, namely, homogeneously fluid GUVs and GUVs 
displaying gel-fluid and lo-ld phase separation were produced. Confocal microscopy was used to 
monitor the possible interactions between coumarin-6-loaded PLGA MPs and GUVs. 
 MPs size (D50%) of non-fluorescent and fluorescent coumarin-6-loaded PLGA MPs ranged between 
1.4±0.3 to 3.8±0.2 µm. The span values ranged between 1.1±0.2 to 4.8±1.1, demonstrating 
polidisperse populations. The surface modification did not demonstrate a statistically significant 
impact on the D50% values. In addition, the presence of coumarin-6 did not demonstrate a statistically 
significant impact on the D50% values, except for PLGA ALG MPs loaded with 0.4 and 1.0 μg/mL of 
coumarin-6 (p < 0.01). As expected, the surface modification produced a statistically significant 
impact on the surface charge (p < 0.001). Negative surface charges were displayed for non-fluorescent 
and fluorescent PLGA PVA MPs (-17.8±0.9 to -19.9±0.2 mV) and for non-fluorescent and fluorescent 
PLG ALG MPs (-30.8±2.3 to -36.8±4.4 mV). PLGA MPs containing CH PLGA showed a highly 
positive surface charge (50.8±2.7 and 58.7±3.4 mV). The presence of coumarin-6 did not demonstrate 
statistically significant impact on surface charge.  
Spectral studies showed that once increasing the MPs concentration in suspension no spectral 
changes were detected, suggesting that coumarin-6 did not change the partition environment to the 
surface and so remains on the hydrophobic matrix. In addition, this observation was further supported 
by the mainly linear variation of fluorescence intensity maximum upon increasing the concentration of 
the coumarin-6-loaded PLGA-C6 MPs, independently of their surface modification. At coumarin-6 
concentrations above 0.2 g/mg, the increase of the non-encapsulated molecules localized in the 
surface of the MPs or even aqueous medium was mainly evidenced by the decrease of anisotropy 
values. Regardless of MP composition, the red shift in probe emition of an aproximately 15 nm once 
increasing probe concentration from 0.04 to 1.00 g/mg also account that observation. 
Studies on the MPs-membranes interaction studies were performed under the following 
experimental conditions: i) concentration of coumarin-6 0.2 g/mg and ii) MPs concentration 0.25 
mg/mL. Data showed that highly positive PLGA CH-C6-3 MPs and highly negative PLGA ALG-C6-3 
MPs interacted with GUVs and were mainly directed to the gel phase and interface of fluid-gel phases.  
 Results show that the MP surface modification plays an important role on surface charge. 
Entrapment of the fluorescent dye coumarin-6 conducts to a probe/MPs stable system. It was 
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demonstrated that surface charge and biophysical membrane behaviour are important on interactions 
of surface modified MPs and GUVs. 
 
Keywords: Poly(lactic-co-glycolic acid) micoparticles, coumarin-6, surface charge, giant unilamelar 
vesicles, interactions. 
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Resumo  
 
Os avanços feitos na área do transporte de agentes terapêuticos têm-se focado no 
desenvolvimento de sistemas à escala nano/micrométrica. Uma das vantagens desses sistemas 
promissores prende-se com a sua específicidade e eficiência na entrega do agente terapêutico à célula, 
tecido ou órgão alvo, permitindo a manutenção da concentração terapêutica desejada durante o tempo 
requerido. Deste modo, a quantidade de agente terapêutico no alvo será apenas a necessária e os 
efeitos secundários serão mínimos. Por outro lado, os estudos das membranas biológicas e dos 
sistemas modelo de membrana têm demonstrado que a membrana celular não é uma mera barreira 
entre o meio extra e intracelular. Na verdade, as evidências apontam para uma grande complexidade 
das membranas celulares, tanto ao nível da sua compartimentação estrutural e funcional bem como no 
papel activo dos lípidos na manutenção do equilíbrio celular. É na junção destes dois contextos – 
membranas celulares e sistemas de entrega à escala nano/micrométrica – que o tópico das interacções 
entre estes dois sistemas se torna tão desafiante e de grande interesse biológico.  
Os estudos nesta área apontam que as características superficiais de nano/micro sistemas 
impactam significativamente as interacções entre estes dois sistemas. Características como tamanho, 
carga superficial, forma e hidrofobicidade de nano/micro sistemas parecem estar na base do 
mecanismo de interacção. Além do mais, alguns estudos apontam que aquando da interacção, estes 
nano e micro vectores podem interferir com a sinalização celular, induzir danos estruturais, alterar a 
expressão génica bem como modificar as características biofísicas das membranas celulares. No 
entanto, diversos estudos têm também demonstrado resultados contraditórios sobre quais dos factores 
primeiramente influenciam a interacção de nano/micro partículas. De facto, esta dependência pode 
também estar relacionada com o tipo de célula. Porém, o tópico das interacções ainda continua pouco 
estudado. A percepção clara dos factores que determinam o sucesso da interacção bem como do efeito 
imediato produzido na membrana celular irão permitir um desenho preciso destes sistemas de entrega 
de medicamentos. Além do mais, também irão possibilitar a modulação com melhor precisão do 
sucesso terapêutico e diminuir efeitos indesejáveis, como toxicidade. Assim, o objectivo deste projecto 
é desenvolver micropartículas (MPs) poliméricas modificadas à superfície para o estudo das 
interacções com sistema de modelo membranares. 
 O poli(ácido láctico-co-glicólico) (PLGA) foi usado como matriz polimérica das MPs. Estas foram 
formuladas usando o método modificado de dupla emulsão por evaporação do solvente. A superfície 
destas MPs foi modificada usando ácido polivinílico (PVA), quitosano (CH) e alginato (ALG), para 
que se obtivessem partículas com carga superficial neutra, positiva e negativa, respetivamente. A 
composição e processo de produção das MPs foram optimizados de forma a obter características 
físico-químicas desejadas, nomeadamente span (medida da dispersão das populações) menor que 1. 
Posteriormente, as MPs foram marcadas com a sonda fluorescente cumarina-6. Esta sonda foi 
encapsulada na matriz polimérica usando cinco concentrações de cumarina-6: 0.01, 0.10, 0.20, 0.40 e 
1.00 µg/mg (µg/mg expressa a concentração de coumarina-6/polímero). Assim, as PLGA MPs não 
fluorescentes e fluorescentes foram caracterizadas tendo em conta o seu tamanho, carga superficial, 
forma, eficiência de encapsulação, capacidade de carga e características espectrais através de 
Difracção Laser, Dispersão Electroforética da Luz, Espectroscopia de Absorção e Microscopia 
Confocal (respectivamente). 
De forma estudar a estabilidade e localização da sonda na matriz, foram preparadas cinco 
concentrações de MPs em suspensão: 0.10, 0.20, 0.25, 0.40, and 0.50 mg/mL. O estudo espectral, 
através de Espectroscopia de Fluorescência, permitiu também a optimização das condições 
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experimentais (em termos de concentração de cumarina-6 e de concentração de MPs em suspensão) da 
última etapa do projecto. Para o efeito, foram adquiridos espectros de emissão/excitação e os valores 
de anisotropia de fluorescência em estado estacionário foram medidos. Posteriormente, Vesículas 
Gigantes Unilamelares (GUVs) contendo diferentes composições lipídicas e propriedades biofísicas 
foram preparadas por electroformação e marcadas com rodamina. Assim, foram preparadas GUVs 
homogeneamente fluídas (POPC), GUVs com separação de fases gel-fluído (POPC/DPPC 1:1 
mol/mol) e separação de fases líquido ordenado–líquido desordenado (POPC/SM/Chol 1:1:1 
mol/mol/mol). Finalmente, para o estudo das interacções recorreu-se a microscopia confocal.  
 Os resultados demonstraram que as PLGA MPs não fluorescentes e fluorescentes têm diâmetros 
médios D50% entre 1.4±0.3 e 3.8±0.2 m. A presença da cumarina-6 não produziu diferenças 
estatisticamente significativas, excepto para PLGA ALG MPs carregadas com 0.4 and 1.0 μg/ml de 
cumarin-6 (p < 0.01). Os valores de span variaram entre 1.1±0.2 e 4.8±1.1, o que demonstra 
heterogeneidade. Os resultados de carga superficial (medida pelo valor de ZP) variaram 
significativamente com a modificação à superfície (p < 0.001). Tanto para MPs fluorescentes como 
para não fluorescentes, a carga superficial situou-se nos intervalos de [(-17.8±0.9)-(-19.9±0.2)] mV, 
[50.8±2.7-58.7±3.4] mV e [(-30.8±2.3)- (-36.8±4.4)] mV para MPs modificadas com PVA, CH e 
ALG, respectivamente. A introdução da sonda não produziu alterações significativas nos valores de 
ZP. A caracterização morfológica revelou que as MPs são esféricas, podendo adoptar, nalguns casos, 
forma de foice (indicador de instabilidade). A caracterização espectral de cumarina-6 demonstrou que 
os comprimentos de onda de excitação/emissão máximos (ex max e em max) não variam 
significativamente com a concentração de suspensão de MPs e com o surfactante usado na 
formulação. Do mesmo modo, à medida que a concentração de MPs na suspensão aumenta, a 
intensidade máxima de fluorescência (F.I.) aumenta de maneira aproximadamente linear. Estes 
resultados demonstram que a sonda está essencialmente localizada na matriz polimérica e, deste modo, 
a sua partição entre o ambiente polimérico hidrofóbico e o ambiente hidrofílico que a rodeia, não é 
alterada. No entanto, com o aumento da concentração de cumarina-6 observou-se, no espectro de 
emissão da sonda, um ligeiro desvio de 15 nm para o vermelho. Os resultados das medidas de 
anisotropia mostram que para concentrações de sonda abaixo de 0.2 m/mg, os valores são de 
aproximadamente 0.35, decrescendo para valores de 0.15, quando a concentração de sonda aumenta de 
0.2 m/mg para 1.00 m/mg. A alteração dos valores de anisotropia e de desvio no espectro de 
emissão observado sugerem que, para altas concentrações, houve um aumento de moléculas não 
encapsuladas localizadas na superfície das MPs ou até mesmo na água. Tendo em conta o estudo 
espectral, a combinação de concentração de sonda/concentração de suspensão escolhida foi de [0.2 
µg/mg; 0.25 mg/ml], pois representaram os valores medianos e os parâmetros analisados variarem 
linearmente. Além do mais, nessa concentração as imagens microscópicas adquiridas não teriam 
demasiada fluorescência.  
Os sistemas de modelo membranares, GUVs, foram preparados com sucesso. As GUVs 
compostas por POPC apresentaram uma distribuição homogénea de Rodamina-DOPE (1,2-Dioleoil-
sn-glicero-3-fosfaetanolamina-N-(lissamina rodamina B Sulfonil), demonstrando a sua fluidez. Por 
outro lado, as vesículas compostas de POPC/DPPC (1:1 mol/mol) apresentaram separação de fases 
gel-fluído. A mistura ternária POPC/SM/Chol (1:1:1 mol/mol/mol) mostrou separação de fases fluído-
fluído. No entanto, nalgumas POPC/SM/Chol (1:1:1 mol/mol/mol) GUVs, também se verificou a 
separação de fases gel-fluído. Finalmente, os estudos das interacções demonstraram nenhuma 
aproximação às vesículas homogeneamente fluidas. As observações feitas demonstraram que apenas 
as PLGA MPs marcadas com sonda com carga superficial altamente positivas e negativas interagiram 
com as GUVs compostas por POPC/DPPC (1:1 mol/mol), na fase gel e interface das fases gel-fluído. 
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Resultados semelhantes foram obtidos com a mistura de POPC/SM/Chol, na qual as PLGA MPs 
modificadas com CH direccionaram-se para a fase líquida-ordenada.  
 Os resultados descritos mostram que o tipo de surfactante usado produz uma clara distinção de 
carga superficial. A sonda cumarina-6 demonstrou ser adequada para marcação deste tipo de MPs pois 
a sua encapsulação permitiu a produção de um sistema sonda/MPs estável. Os estudos de interacção 
revelaram que a carga superficial das MPs e fase biofísica das GUVs determinam as interacções entre 
estes sistemas. 
 
Palavras-chave: Micropartículas ácido poli(láctico-co-glicólico), cumarina-6, carga superficial, 
vesículas unilamelares gigantes, interacções 
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CHAPTER 1: Introduction 
 
In the last three decades, nanotechnology has become a promising approach in diverse 
research areas, like electronics, material engineering, biomedical engineering and pharmaceutics. The 
wide range specific surface area, size, shape, surface chemistry and crystalline structure provide 
nanostructures with unique properties and promising applications in drug delivery (1). 
The efficient delivery of therapeutic agents that target specific sub-cellular compartments such 
as cytoplasm, nucleus, and mitochondria is crucial for their therapeutic success (2). Nano and micro 
drug delivery systems must cross one or various biological membranes (e.g. mucosa, epithelium, 
endothelium) and, after interacting with the plasma membrane, can thus be internalized by a process 
called endocytosis (Figure 1.1) (2,3). During endocytosis, the drug delivery system is first engulfed 
inside the plasma membrane through endosomes, invaginations of the plasma membrane. The carrier 
can then follow different intracellular trafficking pathways and reach specific sub-cellular 
compartments. Part of the therapeutic agent can be removed to the extracellular medium or to other 
cells, in the case of polarized cells.  
Overall, during the endocytic process, drug carrier systems have some barriers to overcome 
until it reaches the target sub-cellular site: association with the plasma membrane and internalization 
through endocytosis; intracellular trafficking and delivery of the therapeutic agent or the drug carrier 
system in the cytoplasmic medium; and translocation to the nucleus or other cellular organelle (2,3). 
During the association with the plasma membrane, the interactions between the drug carriers and the 
Figure 1.1 Representation of the uptake and internalization 
by endocytosis of the drug carrier systems, in this case, 
nanoparticles, NPs. (1) Plasma membrane association with 
the NPs (2) Internalization of the NPs by endocytosis. (3) 
Endosomal escape of the NPs (4) Release of the therapeutic 
agent in the cytoplasm (5). Transport of the therapeutic agent 
to the target sub-cellular compartment. (6) Degradation of 
the therapeutic agent in the lysosomes and cytoplasm. (7) 
Exocytosis of the NPs. PE: primary Endosome; Endo-Lys: 
Endo-lysossome; Lys: Lysossome; RE: reticulum 
endoplasmic. Adapted from (2) 
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plasma membrane largely determine the successful passage to the interior of the cell. However, such 
interactions are still poorly studied. Due to the complexity of the plasma membrane and the properties 
of nano and micro drug delivery systems, the clear perception of how they interact is very important to 
control and understand the mechanisms of uptake by the target cells. As so, some features like size, 
morphology, surface charge (zeta potential, ZP) and surface chemistry of the nano and micro drug 
delivery systems, are widely acceptable as critical factors that control their interaction and further 
uptake by the biomembranes (4–6). 
This dissertion is divided in 8 chapters: 
 
Chapter 1 - Introduction 
Chapter 2 – Literature Review contains a review on the properties of the polymeric microparticles 
and the surface-related features critical to the interactions with the cells. This chapter also includes an 
overview of historical perspective, structure, function and dynamics of the biomembranes. 
Chapter 3 - Aims  
Chapter 4 – Materials and Methods 
Chapter 5 – Results includes a detailed description of the main results of the physicochemical 
characterization of the surface-modified microparticles. Also provides a detailed study on the spectral 
characterization of coumarin-6 entrapped into the MPs. Finally, this chapter contains the MPs-
membrane interaction studies made under confocal imaging. 
Chapter 6 – Discussion  
Chapter 7 – Conclusion 
Chapter 8 – Future Work Perspective 
 
In aditition, suplementary data on spectral data is presented on Annexes. 
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CHAPTER 2: Literature Review 
 
2.1  Drug Delivery Systems – Micro and Nano Systems 
Modern drug delivery research is focused on the development of micro and nano delivery 
systems. These systems have the ability to deliver therapeutic entities to the target cell, tissue or organ 
in a more controlled, specific and reproducible way, while maintaining the release of the desired 
therapeutic concentration in a controlled rate and for an appropriate period of time (5). These systems 
provide minimal side effects by increasing the delivery of the therapeutic agent to the target site, thus 
requiring lower amount of therapeutic entity. 
Nano and micro drug delivery systems should be biocompatible, non-toxic, non-allergic or 
non–inflammatory. In addition, several key parameters should be considered such as: size of the drug 
delivery system, entrapment method, stability of the therapeutic entity, mechanism of degradation of 
the matrix and the release kinetics of the therapeutic agent (6). The materials used as matrix can be 
diverse, including ceramic, gold, carbon, lipidic or polymers. Matrices that are biodegradable and 
bioabsorbable are the most preferred as will not require removal surgical operations. Therapeutic 
entities can be entrapped, protecting their functional properties, decreasing the risk of inactivation and 
toxicity for prolonged time. The release stimuli of the therapeutic agent includes activation of drug 
release by signals as pH variations, temperature, electric field and ultrasound or by degradation of the 
polymeric matrix (5). Additionally, release mechanisms include diffusion of the therapeutic agent and 
erosion of the matrix.  
Examples of nano and micro delivery systems are micelles, liposomes, dendrimers, carbon 
nanotubes, solid-lipid nanoparticles, gold nanoparticles, polymeric nanoparticles (NPs) and polymeric 
microparticles (MPs).  
 
2.1.1  Polymeric Microparticles  
Polymeric MPs are spherical solid colloidal structures composed of a biodegradable polymeric 
matrix with more than 1 m (7). Polymeric MPs are divided in microspheres and microcapsules, 
depending on their morphology, leading to distinct therapeutic agent distributions. In the first ones, the 
therapeutic agent is homogeneously dispersed or solubilized inside the polymeric matrix, while in 
microcapsules the drug is inside an individualized core surrounded by a polymeric membrane. The 
materials used in polymeric MPs formulation can be natural polymers like alginate (ALG), Chitosan 
(CH), collagen, dextran, gelatin and albumin. Regarding the synthetic polymers, these include the 
widely used Poly(lactic acid) (PLA), the copolymer poly(lactic-co-glycolic acid) (PLGA) and poly(ε-
caprolactone) (PCL) (8). Polymeric MPs can be formulated using i) monomers by polycondensation or 
polymerization; or from ii) polymers by single or double emulsion with solvent evaporation, 
microfluid technology and spray-drying (8). 
Regarding the single and double emulsion processes with solvent evaporation, both 
hydrophobic and hydrophilic molecules can be entrapped. Hydrophobic molecules are generally 
entrapped by single emulsion, while hydrophilic molecules are entrapped by double emulsion (9). 
Briefly describing the single emulsion method, the polymer is dissolved in an organic solvent such as 
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Figure 2.1 Double emulsion solvent evaporation  method. (a) and (b) corresponds to 
emulsification steps (11). 
dichloromethane (DCM), oil phase (o) (10). The therapeutic entity is also added to that phase. Under 
appropriate stirring and temperature, this organic solution is emulsified in the presence of a large 
volume of aqueous surfactant solution, the water phase (w) (10). The resulting emulsion is an oil-in-
water (o/w) emulsion. The organic solvent is allowed to evaporate under appropriate stirring and 
temperature conditions. The MPs are normally collected by centrifugation. Concerning to the double 
emulsion method (Figure 2.1), the polymer is dissolved in an organic solvent such as DCM, (o). The 
therapeutic entity is dissolved in the aqueous surfactant solution (w). The (w) is added to the (o) under 
appropriate stirring to allow the generation of the water-in-oil (w/o) emulsion (9,11). This emulsion is 
transferred to an aqueous surfactant solution, being then emulsified under strong stirring. The resulting 
emulsion is a water-in-oil-water (w/o/w) emulsion. The organic solvent is allowed to evaporate under 
stirring during several hours. The MPs are usually collected by centrifugation (9,11). 
 
 
 
 
 
 
 
 
2.1.1.1 PLGA Microparticles 
PLGA is a synthetic biodegradable polymer widely studied in the last decades and used for 
several biomedical applications, namely in the fabrication of drug delivery devices such as NPs and 
MPs (10). PLGA-containing medicines have been approved by the United States Food and Drug 
Administration (US-FDA) for drug delivery due to polymers’ high biocompatibility, biodegradability, 
and control of the drug release (12). PLGA can be implanted and carriers can be administrated by 
parenteral or non-invasive routes. 
PLGA is polyester composed of the copolymers PLA and Poly(glycolic acid) (PGA) (Figure 
2.2) and undergoes degradation through the hydrolysis of its ester linkages, producing those 
monomers that will be metabolized by the body via Krebs cycle. This phenomenon was demonstrated 
in various conditions in vivo and in vitro with different ratios of PLA and PGA and several types of 
bioactive molecules (10,13,14). The mechanism of degradation is the bulk degradation and so, the 
water penetration in the polymeric matrix is faster than the degradation, and therefore the erosion is 
uniform in the entire matrix surface. The release profile of drugs within the PLGA matrix is usually 
described by a biphasic curve, where initially the release is abrupt (called a burst) and the polymer 
molecular weight loss is not significant. The second phase consists on a slow release of the drug, 
commonly by diffusion (by passing water through the pores). The water inside the matrix hydrolyzes 
the polymer, leading to a significant loss of polymer molecular weight. Design factors like molar ratio 
of PLA and PGA, molecular weight of the PLGA, degree of crystallinity, drug hidrophilicity and pH 
of the environment determine the degradation rate.  
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The PLGA-based drug delivery systems have been studied to deliver proteins, peptides, 
deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and drugs (10). PLGA MPs can be prepared by 
single or double emulsion with solvent evaporation, phase separation (coacervation) and spray-drying. 
Usually, these MPs are prepared by the emulsion solvent evaporation method. The polyvinyl alcohol 
(PVA) is the most widely used surfactant to stabilize the emulsion and to reduce the surface tension 
because it generally allows the formulation of MPs with uniform size distribution, it is easy to disperse 
in aqueous medium and easily washed (15). In fact, due to its amphiphilic nature, PVA has excellent 
emulsifying properties being also able to increase the viscosity of the continuous phase. However, the 
use of PVA has raised some concerns regarding its carcinogenic potential and toxicity (16). 
Complications like anemia and infiltration in various tissues and organs were reported when 
subcutaneously injecting 5 % (w/v) PVA aqueous solutions in rats (17). 
The biomedical applications PLGA MPs include the diagnostic and treatment of cancer, 
cardiovascular disease and diabetes, development of vaccines, among others.  
In tumor imaging, the use of imaging techniques like Magnetic Resonance Imaging (MRI), 
ultrasounds and Positron Electron Tomography (PET) in combination with PLGA MPs entrapped 
imaging contrast agents is an important approach for the diagnostic and study of the tumoral area in 
vivo. Lavisse et al. developed PLGA MPs with size distributions of 1 to 15 μm to acoustically 
characterize and select the most suitable to encapsulate the ultrasound contrast agent and then, perform 
a preliminary in vivo study in melanoma grafted mice using Doppler ultrasonography. PLGA MPs of 3 
μm showed the best results, inducing an enhancement of 47% of intratumoral vascularization 
visualization after the MPs injection (18). In cancer disease treatment, PLGA MPs linked with 
antibodies or targeting ligands such as cytokines, hormones, vaccines and chemotherapeutic agents are 
employed to treat malignant tumors with high specificity and affinity (12). Yemisci et al. developed 
PLGA MPs loaded with mitoxantrone to treat malignant glioma (19). In this study, wister were 
divided into three groups: i) rat glioma (RG2) cells and blank PLGA MPs were simultaneously 
implanted, ii) RG2 cells and mitoxantrone loaded-PLGA MPs were simultaneously implanted and iii) 
RG2 cells was implanted and mitoxantrone loaded-PLGA MPs were injected after 7 days. Results 
demonstatred that mitoxantrone loaded-PLGA MPs reduced significantly the tumor volume of the rats 
belonging to group iii). No tumor formation was observed in rats belonging to group ii). In addition, 
results showed no systemic side effects or parenchymal inflammatory infiltration in either groups . 
PLGA MPs were also studied to deliver growth factors (such as cytokines) to the heart to treat 
cardiac failure after a myocardial infarct, in a rat model of myocardial infarction. The results showed a 
high angiogenic and arteriogenic effect (8). 
Figure 2.2 Chemical Structure of the 
copolymer PLGA. X represents the number of 
units of PLA and Y the number of PGA units 
(10). 
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Regarding the development of vaccines, PLGA is the most studied polymer in this field 
because it is a promising candidate to deliver antigens and adjuvants to the target site with a controlled 
release profile (12,20,21). PLGA MPs have been used as a delivery vehicle of antigens in injectable 
administration (20). Peyere et al. developed PLGA MPs prepared by spray-drying or coacervation 
loaded with tetanus or diphtheria toxins, acting as a multivalent vaccine. The PLGA MPs were 
administrated subcutaneously by single injection in guinea pigs and the results showed a high 
immunogenic effect compared with the same dose injected with the licensed divalent vaccine (20). 
 
2.1.1.2 Surface modification of PLGA Microparticles 
PLGA NPs and MPs can be surface-modified by functionalization with target ligands and 
antibodies, or alternatively by coating with hydrophobic and hydrophilic polymers. Surface 
modification can be used in order to manipulate several chemical surface properties, such as 
hydrophobicity, hydrophilicity and surface charge (22). In this way, surface modification will help to 
modulate the entrapment efficiency and the release of the therapeutic entities and also to improve the 
interactions between the PLGA NPs/MPs systems with the cells (23). This section will briefly review 
the properties of the polymers CH and ALG, which can be used to modify the surface of PLGA NPs 
and MPs. 
CH is a natural polymer used in the pharmaceutical field since 1990. It is very attractive to use 
in drug delivery systems because of its biocompatibility, ―non-toxicity‖ and cationic properties due to 
the presence of the primary amino groups. In fact, the presence of its amino groups is responsible for 
important properties such as controlled release and the mucoadhesion. The mucoadhesion is achieved 
due to the interaction of positively charged CH MPs and the negative charge of mucosal surfaces (24). 
As a drug carrier system, CH has been used in the fabrication of membranes, tablets, NPs and MPs 
which can be administrated via oral, nasal, ocular, vaginal, buccal, parenteral and intravesical routes 
(24). CH is obtained by the deacetylation at high temperatures of chitin, which is the main constituent 
of the exoskeleton of crustaceans. Structurally, it is a linear polyaminosaccharide, composed of the 
copolymers of -(1–4) linked 2-acetamido-2-deoxy--D-glucopyranose and 2-amino-2-deoxy--D-
glycopyranose (Figure 2.4) (24–26). CH is soluble in aqueous acidic solutions and insoluble in water 
and organic solvents. However nowadays there are some derivates such as N-trimethyl CH (TMC) that 
are water soluble (27). 
 
 
 
 
 
 
 
 
It is known that the entrapment efficiency of the therapeutic agent in CH MPs  increases with 
the increase of CH concentration (25). Typically, solutions with high concentrations of CH have 
higher viscosity and avoid the formation of drug crystals from leaving the droplets (25). Additionally, 
it is known that the molecular weight of CH influences the release of the therapeutic agent from the 
MPs. A decrease in the release velocity is observed with increasing of the CH molecular weight 
Figure  2.3 Chemical structure of CH (26). 
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because of the higher viscosity of the gel layer in the drug delivery system, which affects the diffusion 
of the therapeutic agent (25). 
Some of the biomedical applications of PLGA NPs and MPs surface modified with CH 
include the diagnostic and treatment of cancer and development of vaccines. Chandy et al. developed 
PLA MPs and PLGA MPs coated with CH or PVA loaded with 5-Fluorouracil (a hydrophilic 
antimetabolite used in cancer therapy), prepared by double emulsion solvent evaporation. Results from 
scanning electron microscopy revealed that CH-coated MPs had less surface pores than the PVA-
coated MPs. This was reflected in the drug release profile, which was slower in CH MPs than in the 
PVA MPs. This work demonstrated that PLGA MPs coated with CH are promising carriers for a 
prolonged release of anti-tumor drugs (28). The high mucoadhesive properties of CH increase 
significantly the amount of macromolecules absorbed in mucosal barriers when administrated with this 
polymer (26,29–31). Kawashima et al. prepared PLGA NPs surface modified with CH, poly(acrylic 
acid) and sodium alginate for oral administration (31). These NPs systems entrapped the peptide 
elcatonin. By measuring the PLGA NPs adsorbed to a rat everted instestinal sac (in vitro), their 
mucoadhesive properties were evaluated. Results showed that surface modified CH PLGA NPs 
showed higher mucoadhesion to the everted intestinal tract in saline than the other PLGA NPs (31).  
ALG is a natural, biocompatible, biodegradable and ―non-toxic‖ polymer used in several 
biomedical applications such as tissue engineering and drug delivery (32). In drug delivery, alginate 
has been used to prepare gels, matrices (as an encapsulating material to cell culture and transplant), 
membranes, NPs and MPs (32,33). ALG is approved by the US-FDA as a safe material for use in the 
alimentary field, having the designation of ―Generally Referred as Safe‖ (34). Structurally, alginate is 
a linear polysaccharide composed by residues of -L-guluronic acid (G) and -D-mannuronic acid 
(M) linked by 1-4 linkages, which generates homopolymeric MM and GG segments interposed by 
heteropolymeric segments of MG or GM (Figure 2.4) (32,33). ALG is pH-sensitive due to the pendent 
acid groups that, in different pH, accept or release protons.  
 
 
 
 
 
 
 
 
 
 
The production of ALG can be from two sources: algae and bacteria. Regarding the extraction 
from bacteria, it is important to mention that it is normally restricted to some research studies, due to 
the high cost of the process. Hence, commercial ALG is mainly extracted by alkaline extraction, from 
brown algae: the algae is collected, dried and submitted to chemical treatments to remove undesired 
Figure 2.4 Structure of Alginate: GG, MM and MG 
segments (34). 
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substances like heavy metals, endotoxins and proteins, and is converted to a powder material in the 
acid or salt form (33).  
The biomedical applications of ALG-surface modified PLGA NPs and MPs include e.g. the 
development of vaccines. Mata et al. developed PLGA MPs and ALG surface modified PLGA MPs to 
malaria vaccination (35). These microparticulate systems entrapped the malaria synthetic peptides 
SPf66 and S3 and the humoral and cellular immune responses were evaluated after intradermal 
immunization. Results showed that the incorporation of ALG caused higher humoral and cellular 
immune responses (35). Additionally, the administration of PLGA MPs coated with Arg-Gly-Asp 
(RGD)-modified ALG showed higher cellular responses such as interferon- secretion and 
lymphoproliferation. Actually, this observation was an evidence of cell targeting (35). ALG has also 
been described as mucoadhesive polymer, improving the delivery of molecules to the mucosal tissues 
(23,36). Ungaro et al. developed PLGA NPs surface modified with ALG or CH to the production of 
dry powders for the tobramycin antibiotic inhalation (36). PLGA NPs were embedded in an inert 
microcarrier made of lactose. Results showed that surface modified ALG PLGA NPs allowed efficient 
antibiotic entrapment and achieved its release up to one month. The in vivo biodistribution studies 
demonstrated that plain PLGA NPs and ALG surface modified PLGA NPs reached up the deep lung. 
On other side, CH surface modified PLGA NPs reached the upper airways, the lining lung epithelial 
surfaces (36).  
2.1.2 Impact of Physicochemical Surface Properties of Nano and 
Micro Systems in Cellular Uptake – size, surface charge, shape 
and chemistry 
Understanding the mechanism of interaction between cell and the nano and micro drug 
delivery systems is essential to the efficient design and safe application of drug targeting strategies 
(37). The cellular uptake can be described as a combination of attractive and adhesive interactions 
between the carrier and the plasma membrane and the driving force for wrapping (38,39). The driving 
force for wrapping can be described as the amount of free energy required to produce the deformation 
and drive the carrier to the internal medium of the cells (38). This process is dependent of some factors 
such as the size, shape, surface charge and surface chemistry of the carrier, rigidity of the plasma 
membrane and receptor abundance (38,39).  Thus, the study and optimization of the impact of these 
parameters can lead to the development of smarter and safer drug delivery systems. This section is 
focused on the significance of the characteristics of the surface of the nano and microcarriers in the 
context of their interaction with plasma membranes (Figure 2.5). 
 
 
 
 
 
 
Figure 2.5 Factors that influence the cellular uptake of the nano and micro drug delivery 
systems. The cellular uptake is dependent of factors of the carrier such as size, shape, surface 
charge and chemistry. In the feature chemistry we can considerate the surface composition, 
ligand density, hydrophobicity and hidrophilicity. On the other side, cell properties like the 
receptor internalization levels, internalization mechanism, phenotype, localization and also the 
rigidity of the plasma membrane also affect the cellular uptake. (58) 
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It has being reported that the drug carrier size is not the only factor involved in the cellular 
uptake, however it is determinant to that process (1,4,37,40–43). Theoretical models and its supported 
experimental evidence have suggested that to achieve effective cellular uptake, NPs must have a 
minimum size of 30-50 nm (44–48). This minimum range of size seems to be necessary to produce the 
required driving force for wrapping, leading to the deformation and invagination of the plasma 
membrane. Each cell can have differential levels of expression of target receptors, leading to an 
enhancement of the recognition of certain ligands. It should be noted that the range of sizes above 
mentioned corresponds to the scenario where the concentration of ligand on the NPs surface, when 
present, and the receptor abundance are not limiting factors. In addition, it was observed in 
Acanthamoeba that large carriers roughly with 250 nm -3 m are faster internalized than particles with 
diameters less than 250 nm (41,49) . The different mechanisms of internalization displayed by the 
cells also contribute to different uptake mechanisms of drug carriers in terms of size (1,3,42). Actually 
the nonphagocytic mechanism allows the internalization of fluids and soluts. The phagocytic 
mechanism allows the internalization of large particles i.e more than 0.5 m. In this way, NPs are 
preferently internalized by other endocytic processes that are not restricted to phagocytic cells (42,50). 
However, MPs are preferentially internalized by phagocytosis in phagocytic cells such as 
macrophages, neutrophils, monocytes and dendritic cells. MPs can be also non-specifically 
internalized by macropinocytosis, when their diameters range from 0.5 m to 10 m (3). There is 
evidence that other types of cells, referred as nonprofessional phagocytes like fibroblasts, epithelial 
and endothelial cells can display the phagocytic mechanism but at a lower extent (3,41). Dendritic 
cells have shown an optimal uptake of particles with diameters up to 10 μm (37). Regarding 
macrophages, they have shown that the optimal diameter of particles is up to 30 μm (37). Considering 
the efficient permeation in biological barriers, the nano sized drug delivery systems are usually more 
efficient than the larger ones and so NPs have higher rate of uptake compared to MPs (15,51). NPs 
penetrate throughout the submucosal layers while MPs stay mainly in the epithelial lining; some NPs 
can cross the blood-brain barrier through the opening of tight junctions by hyperosmotic mannitol, 
passing through the capillaries after their injection and achieving the stability in blood circulation 
(15,51). Thus, for targeted drug delivery, the size of 100 nm or less are usually preferred (15,51).  
Polymeric particle surface charge is a parameter that highly affects the uptake and therefore, 
the selectivity and efficiency of all drug delivery systems (50). Surface charge is the result of the 
chemical nature of the polymer matrix, the stabilizing agent and the pH of the dispersant medium (37). 
Evidence suggests that cells preferentially take up charged micro and nanocarriers instead of the 
neutral ones (3,42,52,53). To the positive carriers is associated a high rate of uptake and 
internalization, that can be explained by the ionic interactions between cationic polymers of the 
particles and the negative charge of the plasma membrane of the target cells (37). MPs and NPs 
containing cationic polymers, like stearylamine-coated PEG-co-PLA, PLGA modified with PLL and 
CH, are a good example of this finding (42) . Yue et al. prepared positive, negative and neutral CH 
NPs with an average diameter of 215 nm and showed that positive charged CH NPs (ZP39.25 mV) 
allowed a significant increase of the amount and rate of cellular uptake in all the cell lines tested (54). 
However, there is also evidence of the uptake of negative nano and microcarriers. This mechanism is 
associate to a slower internalization, as compared with the positive counterparts (1,3). The 
involvement of non-specific interactions with non-specific receptors by electrostatic interactions can 
explain the uptake of negatively charged carriers. Electrostatic interactions with the positive site of the 
proteins of the plasma membrane can trigger their uptake (55). In addition, phenomenon like oxidative 
stress to the plasma membrane can favor the adhesion of negatively charged carriers (56). Lao et al. 
demonstrated that under normal conditions, fullerene NPs are repulsed by cerebral microvessel 
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endothelial cells. Under oxidative conditions, the negative charge of the cell surface is decreased and 
these NPs adhere (56). 
The shape of two interacting bodies can significantly affect the superficial adhesion (57). 
Actually, the nano and micro drug delivery systems, specially the polymeric ones, are centered in 
spherical shapes (58). Champion et al. developed polystyrene MPs of various sizes and shapes, as 
spheres, oblate ellipsoids, prolate ellipsoids and rectangular discs. They demonstrated that, instead of 
size, the shape is a highly significant parameter in the uptake of these MPs by alveolar macrophages 
(59). The orientation of the MPs in the point of contact with the cell also plays an important role in the 
internalization – this local shape dictates the actin structure that must be created to initiate the 
internalization process, allowing the membrane moving over the MPs. When the required actin 
structure is not created, the internalization does not happen and there is just a spreading. It must be 
emphasized that size is more important than shape when the volume of the particle exceeds the volume 
of the cell (59). Other studies have suggested that cells display selectivity in terms of the shape of the 
drug carrier captured. Hutter et al. prepared rod, spherical and spiky shaped gold NPs and showed that 
spiky gold NPs are preferentially taken up by microglia cells (60). However, only rods are internalized 
by the nonphagocytic neuron cells. It should be noted that some studies have shown that these new 
shaped drug delivery devices are associated to significant toxic effects due to its accumulation (61).  
Chemical properties such as surface composition, functionalization, hydrophobicity and 
hydrophilicity play an important role in cellular uptake of MPs and NPs (22). Evidence shows that 
nano and microcarriers with different surface chemistry have increased uptake when they are more 
hydrophobic (37). In PLGA NPs and MPs, it was shown that hydrophobicity affects the cellular 
uptake due to the fraction of PVA that remains on the particle surface. PLGA NPs and MPs are more 
hydrophilic when they have a greater amount of PVA associated to its surface and so, the cellular 
uptake of these particles is reduced (15). Y. L. Chiu et al. demonstrated that NPs prepared with a 
hydrophobically-modified CH with more palmitoyls groups present on the surface of the particles 
have higher interaction with cell membranes (62). The surface of the nano and micro drug delivery 
devices can be functionalized with some target ligands - biomolecules like peptides or chemical 
groups - to confer a more specific delivery of the target cell and enhance the uptake. Surface 
functionalization can reduce the surface reactivity, the toxicity or enhance the stability. In fact, the 
surface adsorption of proteins, like transferrin, or other molecules, such as citric-acid, by the nano and 
micro drug delivery devices can lead to a higher uptake by the cells. Coating with cell penetration 
peptides such as poly(L-lysine) and arginine-rich peptides or cell-fusogenic peptides like the ones 
found in some viruses, is an efficient approach to increase the uptake by the cells. Some cell 
penetration peptides have hydrophilic residues interchanging with hydrophobic residues, which can be 
an interesting approach in the modulation of cell uptake (1). On other side, the surface modification 
with the hydrophilic non-ionic polymer poly(ethylene glycol) (PEG) is a common approach to 
promote the escape of NPs from the reticulo-endothelial system, increasing their time in the blood 
circulation (42). 
 
2.2  Biomembranes – structure and importance 
Biomembranes are complex and dynamic organization of lipids and proteins and glycids that 
surround the cells and create a boundary between the intracellular medium and the extracellular 
medium (63–65). Biomembranes act as a matrix for the organization and to the dynamic interactions 
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between their molecules, connecting its different compartments (66). Eukaryotic cells have a plasma 
membrane and intracellular membranes that encase cellular organelles, while prokaryotic cells have 
just the plasma membrane. 
Plasma membrane regulates the type of molecules that cross the cell and the amount of each 
molecule. This barrier function of biomembranes underlies the formation, maintenance and use of the 
transmembranar solute gradients, essential to cell metabolism and production of energy (64). 
Biomembranes are also responsible for the selection and release of molecules via endocytosis and 
exocytosis, and are sensitive to chemical changes in the environment such as pH, temperature, 
pressure, salinity, ionic strength and hydration state (64). The accumulated evidence have suggested 
that the function of the cell membranes is achieved by interactions among the membrane components 
that build functional compartments with specific lipid and protein composition and biophysical 
properties (63). Their lipids can be bioactive entities (67). The bioactive lipids can act as first or 
second messengers in signal transduction (67). On other hand, bioactive lipids can act as regulators of 
the biomembrane organization, allowing the aggregation or segregation of certain proteins (67).   
 
2.2.1 Historical Perspective 
The investigation of the structure of the biomembranes started on the 19
th
 century, when 
Charles Ernest Overton (1895) during his doctoral degree, investigated substances that freely passed 
into cell plants (68). He found that the membrane has a selective permeability and that this is related to 
the partition coefficient between water and oil and the chemical nature of each substance. Overton 
suggested that the cells were surrounded by membranes composed by lipids and cholesterol. Later, in 
1917, Irving Langmuir, during his research in molecular monolayers of lipids, studied the interaction 
between oil films and water. He proposed that a monolayer is composed by molecules of fatty acids 
oriented vertically with the polar headgroups to the surface of the water and the hydrocarbon chains 
oriented to the air phase (68). In 1925, Gorter and Grendel proposed that cell membranes are 
composed by a lipid bilayer where the polar headgroups were oriented to the aqueous medium. 
Danielli and Davson proposed the first membrane model accepted by the majority of the scientific 
community – arrangement of an amphiphilic phospholipid bilayer covered on both sides with proteins 
- the Sandwich Model. With the development of the electron microscopy, J. David Robertson 
confirmed the experimental findings of Gorter and Grendel and Danielli and Davson (68). In fact, he 
extended the concept of cell membranes to subcellular organelles like mitochondria and nucleus and 
concluded that there was evidence for a common structure for all biomembranes. In 1972, Singer and 
Nicolson proposed the Fluid Mosaic Model (Figure 2.6) which describes that biomembranes are fluid 
entities composed by a supporting matrix of a phospholipid bilayer that act as a solvent for proteins 
(69). The model also highlighted the distinction between integral proteins, as the ones that penetrate to 
the core of the lipid bilayer, and peripheral proteins, as the ones that are attached to the plasma 
membrane surface on the cytoplasmic side (69). This model considers that lipids and proteins can 
freely diffuse laterally in the biomembrane.  Additionally, the model also considers that some lipids 
may interact specifically with the membrane proteins (69).   
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Although the Fluid Mosaic Model is still the main concept that explains the basis of the 
structure of biomembranes, the subsequent research supported by new experimental techniques 
provided novel structural features. Taking into account the asymmetric distribution of the different 
lipid species along the inner and outer leaflet of biomembranes proposed before, in 1997 Kai Simons 
and Elina Ikonen, in the Raft Model, proposed the existence of specialized lipid domains that appear in 
a time and space-dependent manner (70). This model also proposes that these specific domains are 
responsible for lipid-lipid and lipid-protein interactions (70). In fact, currently biomembranes are 
viewed as highly compartmentalized entities due to the heterogeneities in organization, asymmetric 
distribution of lipids and protein organization (Figure 2.7). In addition, biomembranes are also 
currently viewed as dynamic entities due to its components interactions. 
In 2005, Kusumi et al. proposed the Fence Model that describes that the cell membranes 
compartments are delineated by the cytoskeleton meshwork that act as ―fences‖ anchored to the 
intrinsic proteins acting as the ―pickets‖ to the lipid movement (71). This protein arrangement confines 
the lipids for a certain time in a compartment, serving as a diffusion barrier, where molecules diffuse 
rapidly by Brownian motion and escape from one compartment to the next by hop diffusion or through 
transient gaps in the barrier (71). 
 
 
 
 
 
 
 
 
 Figure 2.7  Schematic representation of the update view of the Fluid 
Mosaic Model. Lipid bilayer is highly compartmentalized, due to the 
heterogeneous lipid distribution along the bilayer. Like in the first version 
of this model, proteins here appear with a non-homogeneous distribution 
and are also classified as integral and peripheral. Adapted from (80)   
Figure 2.6 Schematic representation of the Fluid Mosaic 
Model, proposed by Singer and Nicolson. This model proposes 
a non-compartmented perspective of biomembranes composed 
by a lipid bilayer and integral and peripheral proteins, non-
homogenously distributed along the biomembrane. (69) 
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2.2.2 Types of Biomembrane Lipids 
Biomembranes are composed by lipids, proteins and glycids, these last always in the form of 
glycolipids or glycoproteins. The major components of biomembranes are lipids and they exist with a 
high variety that, in eukaryotic cells, can be achieved through modifications in the hydrophilic head 
group and the hydrophobic carbon chains (67,72). Biomembranes lipids can be divided in three main 
classes of lipids: 
 Glycerolipids – mainly the glycerophospholipids (65). They are composed of fatty acyl 
chains of a number of carbon atoms ranging from 14 to 22. These acyl chains can be 
saturated or unsaturated with variable degree of unsaturation, in the sn-1 and sn-2 
positions (stereospecific number, sn) (67,72). The cis isomer is the most common isomer 
but the trans isomer can also be present (67,72). The two nonpolar chains compose the 
hydrophobic part and are linked to a glycerol via ester or alkyl ether or alkenyl ether bond 
(67). In the sn-3 position of the glycerol backbone, is placed the phosphate group that can 
be linked to different chemical groups (hydrophilic part), leading to different 
glycerophospholipids, including: phosphatidylcholine (PC), phosphatidylethanolamine 
(PE), phosphatidylserine (PS), phosphatiglycerol (PG), phosphatinositol (PI), and the 
unmodified, phosphatidic acid (PA) (67,72). PC is the most abundant in eukaryotic cells, 
accounting more than 50% of the total glycerophospholipids of biomembranes (64,67). In 
fact, the chemical headgroups define the charge of the whole lipid. Accordingly, at 
physiological pH, PA, PS and PG are anionics, whereas PC and PE are zwitterionic (65); 
(Figure 2.8)  
 Sphingolipids – are composed of a shingoid base that is amine linked to a fatty acid (73). 
The sphingoid base, in mammalians, is typically sphingosine or sphinganine. Sphingosine 
has 18 or 20 carbon atoms, a trans double bound between the carbons 4 and 5 and two 
hydroxyl groups placed at carbons 1 and 3  (73). Sphinganine is the saturated form of 
sphingosine. The fatty acid has typically 16-24 carbon atoms and can be saturated or 
monosaturated. Ceramide is the simplest sphingolipid and the backbone of all complex 
sphingolipids. Ceramide can be phosphorylated to yield Ceramide 1-Phosphate; 
glycosylated to form complex glycosphingolipids; or form sphingomyelin (SM) or 
ethanolaminephosphoryl ceramide (EPC) through the addition of a phosphocholine or 
phosphoethanolamine headgroup to the ceramide backbone, respectively (72,73). (Figure 
2.8)    
 Sterols – composed of a steroid ring (hydrophobic part) linked to a hydroxyl group 
(hydrophilic part). Cholesterol (Chol) is the most common in mammalian cells (65,67). 
(Figure 2.8)     
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2.2.3 Membrane Lipid  Phases 
Lipids can adopt different supramolecular structures, which are influenced by a number of 
factors like temperature, pressure, pH, salinity, ionic strength, hydration state and shape (64,67). Lipid 
phases can be divided in lamellar (L) and non-lamellar (67). The main L phases are: i) gel or solid 
ordered (L) ii) fluid (L) that is further divided in liquid ordered (lo) and liquid disordered (ld). The 
main non-lamellar phases are the hexagonal and cubic. 
The L is the most representative in cell membranes under normal conditions. Structurally, the 
headgroups face the aqueous medium in both sides of the biomembrane and the acyl chains oppose 
each other, forming a lipid bilayer (74). The thickness of the bilayer is roughly similar to the 
hydrocarbon length (74). The presence of unsaturations along the acyl chains reflects a decrease in the 
thickness of the bilayer. When a cis double bound is introduced, it produces a permanent kink in the 
acyl chain, increasing the cross-sectional area of the lipid and decreasing the average length of the acyl 
chain, in order to maintain the total volume (74).  
In the gel phase, L, the hydrocarbon chains of the phospholipids are in the all trans 
configuration and so, are fully extended. Thus, this leads to a small cross-sectional area per lipid 
molecule and a maximum bilayer thickness (Figure 2.9) (75). The hydrocarbon chains with small 
headgroups are aligned perpendicular to the surface of the lipid bilayer, being ordered side-to-side. To 
optimize the packing of the lipids, the ones with larger headgroups (like PC) have their hydrocarbon 
chains tilted (75). In this phase, the lipid motion is greatly restricted, giving rise to a highly 
Figure 2.8 Schematic representation of the three main types of lipids in eukaryotic membranes. (a) 
Glycerophospholipids. They are composed of two fatty acyl chains, represented in pink that are linked to the glycerol 
(blue shading). In the sn-3 position of the glycerol is placed the phosphate group, represented by the orange circle. The 
phosphate group can be associated to serine, inositol, ethanolamine, choline and glycerol, leading to phosphatidylserine 
(PS), phosphatinositol (PI), phosphatidylethanolamine (PE), phosphocholine (PC) and phosphatiglycerol (PG), 
respectively. These substitutions on the phosphate group are symbolized by the R blue circles. Glycerophospholipids 
without the headgroup form the phosphatidic acid (PA). (b) Sphingolipids. They are composed of a sphingoid base 
represented in blue shading, amine linked to a fatty acid (pink shading). This is the constitution of Ceramide (Cer), the 
simplest sphingolipid. The introduction of phosphocholine or phosphoethanolamine (blue circles) to the headgroup of 
the ceramide backbone yields sphingomyelin (SM) and to ethanolaminephosphoryl ceramide (EPC), respectively. The 
introduction of glucose or galactose groups (green hexagons) gives rise to the formation of complex 
glycosphingolipids. (c) Sterols. They are composed of a sterol ring linked to a hydroxyl group. In mammalians, 
cholesterol is present, ergosterol in fungi and stigmasterol and sitosterol in plants. Adapted from (120). 
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Figure 2.9 Schematic representation of the gel 
phase where is noted the maximal bilayer 
thickness and the high packing of the lipids. 
Adapted from (67) 
Figure 2.1 0 Schematic representation of the liquid disordered (ld) (on the left) and the liquid ordered 
(lo) (on the right) phases. The lo phase just occurs in the presence of cholesterol (represented in blue) 
and has a high order (like in gel phase) and a high translational mobility, characteristic of fluid 
phases. The ld phase is mainly composed by phospholipids and the order of the acyl chains is lower 
and the degree of freedom of the lipids is higher, comparatively to lo phase. Adapted from (67) 
 
impermeable ordered structure. It is noted that Lis formed at low temperatures and in presence of low 
amount of water.  
 
 
 
 
 
 
 
 
The fluid phase,L, occurs in the presence of higher water content, the thickness of the bilayer 
and the order of the acyl chains decreases relatively to the Lphase (76). In fact, due to the separation 
distance and the increase of the cross sectional area of the chains, the fatty acyl chains are arranged 
parallel to the bilayer surface and in lipids with larger headgroups, its hydrocarbon chains  do not need 
to be tilted. Lipids display a fast lateral diffusion and move freely within the membrane leaflet with a 
direction perpendicular to the plane of the membrane. In other words, Lis a two dimensional fluid 
(66,74). According to the degree of internal freedom, Lcan be further divided into liquid ordered (lo) 
and liquid disordered (ld) phases (Figure 2.10) (77). In lo phase, the hydrocarbon chains are highly 
ordered and extended (as in the Land exhibits high lateral mobility, characteristic of fluid states 
(65,67). This lipid arrangement is adopted in the presence of cholesterol, which is able to insert in the 
free spaces between the acyl chains, acting as a stabilizer of this phase (66). Cholesterol has a 
preferential partition to the lo phase, where the highly ordered acyl chains of the lipids provide a 
tighter packing of the sterol ring. In the ld phase, the acyl chains are highly disordered and the motion 
of the acyl chains of the lipids is higher than in the lo phase. ld is mainly composed of 
glycerophospholipids with unsaturated acyl chains (65,67).  
Besides all the controversy, the accumulated studies consider that biomembranes are normally 
in the fluid phase (lo phase ld) (65). It should be noted that the actual literature considers that the L is 
not physiologically relevant (76). Actually, it was argue that the high lipid packing is not consistent to 
the proper function of proteins. However, some studies point that L is physiologically relevant  (78).    
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Non-lamellar phases are present in transient biomembrane phenomena like membrane fusion, 
fission, pore formation and formation of tight junctions (67). In the Hexagonal Phase (HI) lipids are 
organized as many micelles joined to form long tubes, where the polar headgroups are facing out and 
the acyl chains the interior. This phase is formed under low hydration (74).In the Inverted Hexagonal 
Phase (HII), lipids are packed inversely in relation to HI – the polar headgroups are facing the interior 
of the long tube and the acyl chains the outside (Figure 2.11). Because of this arrangement, the center 
of the tube is aqueous, surrounded by the hydrophilic polar headgroups and the surface is 
hydrophobic, leading to aggregation of the tubes (giving rise to a hexagonal cross section) in order to 
exclude the water from the surface  (74). In the Cubic Phase, lipids are arranged like short tubes joined 
in a hexagonal array. This phase can be found in mixtures passing from the L phase to the HII (74). 
 
 
 
 
 
 
 
The main transition temperature (Tm) defines the temperature at which the transition between 
the gel and the fluid phase occurs. In homogenous systems, typically composed by a single lipid 
species, this transition  occurs at a defined temperature, and so, bellow this temperature the system is 
in the gel phase, while at temperatures above Tm  only fluid phase is present (79). Tm is highly 
dependent of the characteristics of the acyl chain, Van der Waals interactions and also the type of the 
headgroup. For longer acyl chains, the contact area is higher and so the strength of the Van der Waals 
interactions increases. This leads to an increase of Tm leading to a decrease of the lipid mobility 
(64,75). The presence of unsaturations is related to a decrease of Tm. In fact, the existence of a cis 
double bound give rise to free spaces, allowing additional flexibility in the adjacent hydrocarbon 
chains, abruptly decreasing the Tm. The trans double bonds also decrease the Tm, but not so abruptly 
(66). 
In membrane model systems containing more than one type of lipids the melting occurs over a 
range of temperatures, and the midpoint of the transition, corresponds to the main transition 
temperature. Over the range of melting temperatures, different proportions of lipids in L and 
Lcoexist (75). 
 
2.2.4 Membrane Lipid Domains 
As referred in the above sections, biomembranes are fluid entities with nonhomogeneous 
lateral lipid and protein distribution, being therefore highly compartmentalized. These regions, also 
known as lipid domains, display specific lipid and protein composition that confer the characteristic 
biophysical properties of membrane domains (66). The existence of these compartments is directly 
Figure 2.11 Schematic representation of the 
Inverted Hexagonal Phase. The hydrocarbon 
chains are facing the exterior and the polar 
headgroups the interior. Adapted from (74). 
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connected to different functional features of biomembranes, like transduction of signal, endocytosis 
and intracellular trafficking (66,80). 
Lipid Rafts (Figure 2.12) are a good example of membrane domains. Lipid Rafts consist of 
ordered membrane regions, enriched in sphingolipids and cholesterol. These domains are thought to be 
small (nanosized) dynamic entities that exist transiently and that can be stabilized in response to a 
variety of stimuli. In fact, an important feature of lipid raft domains is the inclusion or exclusion of 
proteins. This feature has been considered as one of the essential factors for formation, maintenance 
and dynamics of lipids rafts domains (70). On other side, protein-protein interactions have been 
attributed as an important factor for raft stabilization (66). Proteins that have preferential partition into 
lipid rafts are glycosylphosphatidylinositol (GPI)-anchored proteins (or others with hydrophobic 
modifications) that partition into these domains due to preferential packing of their saturated 
membrane anchors (81). Other proteins are the double acylated proteins (such as proto-oncogene 
tyrosine-protein kinase (Src)-family kinases), cholesterol-linked and palmitoylated proteins and 
transmembrane proteins (specially the palmitoylated ones) (81). Nonetheless, the dynamic nature of 
lipid rafts, together with their small size, precludes their visualization under physiological conditions 
with the currently available technologies (81). Therefore,  their existence in living cells is still 
controversial (73). Nonetheless, because lipid rafts have a lipid composition and properties different 
from the surrounding biomembrane – actually they are lo regions dispersed in a ld matrix of 
glycerophospholipids with unsaturated acyl chains, leading to a fluid-fluid phase separation – they are 
thought to be important modulators of cellular events (65,66,81).  
The biological significance of lipid rafts domains is related, for example, with protein sorting 
and transduction of signal pathways like in the immune system during bacterial and viral infections of 
HIV and influenza (73,80). 
 
 
 
2.2.5 Membrane Model Systems 
The complex nature of biomembranes that includes multiple lipid species and proteins, 
together with cellular events that constantly change the lipid and protein composition of biological 
membranes, is a major drawback for studies that aim to understand the biophysical principles 
underlying membrane organization and structure, as well as for studies that aim to evaluate the 
interaction of biologically relevant entities with the membrane (65). The use of artificial systems that 
mimic some features of biomembranes, constitutes a more controlled and simple manner to tackle 
Figure 2.12 Schematic representation of Lipid Rafts. In the lo phase it is visible an enrichment in Chol (green) 
and a high packing of the hydrocarbon chains of the lipids. Glycosphingolipids are represented in pink. The 
surrounded ld phase has a lower content of cholesterol and lipids have a disordered arrangement of its 
hydrocarbon chains (121). 
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Figure 2.13 Schematic representation of the different types of liposomes, 
according to its size and number of bilayers. Adapted from (70). 
 
these subjects. Membrane model systems mimic the lipid organization of the biological membrane, 
and their composition can be selected according to the aim of the study (65). These models have been 
created to keep the bilayer structure, but simplifying the system to facilitate the study of the individual 
role of components. Lipid Monolayers, Supported Lipid Bilayers and Liposomes are examples of 
membrane model systems (65).  
Liposomes (Figure 2.13) are approximately spherical lipid assemblies (as lipid bilayers) that 
enclose an aqueous compartment. Liposomes can be made of one or more lipid components, and 
might also contain peptides or proteins. These systems are widely used to study the biophysical 
properties of membranes, particularly to address specific lipid-lipid and lipid-protein interactions 
(65,82). The advantages of the use of liposomes are the easy formulation and the reproducible 
properties. On other side, some liposomes (mainly the multi bilayered ones) can display heterogeneity 
in terms of size distribution (74). In addition, liposomes display poor long-term stability (65).  
According to the number of bilayers, they are divided in Unilamellar Vesicles (just a single lipid 
bilayer) and Multilamellar Vesicles (MLVs) when there is more than one lipid bilayer. Regarding the 
diameter of the liposome, are designated as Small Unilamellar Vesicles (SUVs, 25-100 nm), Large 
Unilamellar Vesicles (LUVs, 100-1000nm) and Giant Unilamellar Vesicles (GUVs, 1-100 m) (83). 
 
 
 
 
 
 
 
 
GUVs are the membrane model systems that display a size similar to cells (82). In fact, the 
membranes of GUVs are good approximations of the self-closed lipid structures of biomembranes. 
They are stable under different values of pH, pressure and temperature (84). When a fluorescent probe 
is properly incorporated during the vesicle preparation or after that, GUVs can be observed through 
fluorescence or confocal microscopy, allowing the real-time monitoring of its morphological changes 
and phase behaviour (82,84). These liposomes can be prepared by eight different methods such as 
fusion of SUVs or LUVs, transformation of a lipid stabilized water/oil/water double emulsion into 
GUVs, GUVs formed from micellized bilayer-forming lipids and electroformation, that is the most 
used  (82). 
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CHAPTER 3: Aims 
 
For the successful development of nano and micro drug delivery systems, a through 
knowledge of the surface-related physicochemical features that are determinant for the interaction of 
these carrier systems with cells is also needed. In the past few years, the study of the interactions 
between nano and micro drug delivery systems and biomembranes has been under focus 
(1,4,42,43,85). Notwithstanding, comprehensive studies on how the surface-related physicochemical 
properties influence the interaction of these systems with cell membranes and the consequent effects 
produced on these membranes are still missing. Such knowledge will contribute to the establishment 
of strategies and guidelines that allow a safer and more efficient design of nano and micro drug 
delivery systems. 
This project aims to study how the surface-related physicochemical features of MPs modulate 
their interactions with GUVs, used as membrane model systems. To achieve this main goal, polymeric 
MPs were prepared, optimized to confer neutral, negative and positive surface charges and 
characterized for their physicochemical properties. MPs were then labeled with the fluorescent dye 
coumarin-6 to assess the interaction with GUVs, using confocal microscopy technique. Prior to the 
analysis of MPs-membrane interactions, a fundamental control was performed by studying the 
photophysical properties of coumarin-6-loaded MPs after the optimization of the experimental 
conditions regarding coumarin-6-loaded MPs (dye concentration and MPs:dye ratio). Finally, the 
effect of the MP surface charge on the MPs- membrane interactions were evaluated using GUVs with 
different lipid composition and membrane properties, namely, homogeneously fluid GUVs and GUVs 
displaying gel-fluid and lo-ld phase separation based on previous findings (86,87). 
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CHAPTER 4: Materials and Methods 
 
4.1  Materials 
Poly(D,L-lactide-co-glycolide) (PLGA) Resomer®  RG 504 (lactide:glycolide 50:50) (batch 
1042040), Polyvinyl alcohol (PVA) 13-23k 87-89 % hydrolyzed (batch MKBJ9294V), Alginic Acid 
Sodium Salt (batch 051M1864V), Coumarin-6 98 % (batch MKBJ5465V) and Cholesterol (Chol) >99 
% (batch SLBC 7554V) were purchased from Sigma-Aldrich (St. Louis, MO, USA). CH Low Viscous 
(batch 131663) was obtained from Fluka (Buchs, Switzerland).  
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) and 16:0 SM (N-palmitoyl-D-
erythro-sphingosylphosphorylcholine) were obtained from Avanti Polar Lipids (Alabarster, AL, USA). 
DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) (batch 563098-01/131) from Lipoid. Avidin 
Egg White was purchased from Sigma Chemical Co. Rho-DOPE (1,2-Dioleoyl-sn-Glycero-3-
Phosphoethanolamine-N-(Lissamine Rhodamine B Sulfonyl)) and DOPE-biotin (1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(biotinyl)) at a biotinylated/non-biotinylated lipid ratio of 1:10
6
 
were obtained from Molecular Probes (Leiden, The Netherlands). 
Dichloromethane (DCM) (for analysis) (batch K43751220236) and Chloroform Uvasol® 
grade were obtained from Merck. Acetic Acid from Hipersolv Chromanorm (batch 07B010521) was 
obtained from VWR Prolabo (Radnor, PA, USA). Deionized water was obtained in the equipment 
Merck Millipore (Darmstadt, Germany). 
 
4.2  Methods  
4.2.1  Lipids and probe stock solutions 
Stock solutions of lipids and Rho-DOPE were prepared in chloroform and stored at -20 C 
protected from the light. Depending on the application of coumarin-6, stock solutions were prepared in 
ethanol to produce PLGA MPs or DCM for absorption spectroscopy studies and stored at -20 C 
protected from the light. The concentration of dye stock solutions was determined 
spectrophotometrically, measuring the absorption spectrum over a range of wavelengths and applying 
the Beer-Lambert law:        (Equation 4.1), where A is the absorbance, ε the molar absorption 
coefficient,   the optical length and c the concentration (88). Probe concentrations were determined 
using  (Rho-DOPE λmax=559 nm, chloroform)=9510
3
 M
-1
cm
-1
 (89) and  (coumarin-6 λmax=458 nm, 
ethanol)= 54103 M-1cm-1 (90). An  (coumarin-6 λmax=455 nm, DCM)=55.610
3 
 M
-1
cm
-1
 was also 
determined using several dilutions of coumarin-6 stock solution in DCM. An absorption calibration 
curve was obtained from the plot absorption vs probe concentration, and the   determined from the 
slope according to the Beer-Lambert law. 
4.2.2  Surface-modified MPs preparation 
 Polymeric MPs with different compositions (Table 4.1) were prepared in triplicates using the 
w/o/w double emulsion solvent evaporation technique. Three different surface modifications of MPs 
were performed to manipulate MPs’ surface charge: PVA, CH and  ALG. PLGA MPs were first 
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optimized in terms of size and surface charge and then in terms of optimal loading of coumarin-6. 
Different initial amounts of coumarin-6 were used to prepare coumarin-6-loaded MPs: 10, 25, 50, 100 
and 250 g (for 250 mg of polymer). Coumarin-6 concentration was expressed as mass (g) per mg of 
PLGA: 0.04, 0.10, 0.20, 0.40 and 1.00 g/mg.  
Briefly, 250 mg of PLGA were dissolved in 5 mL of DCM and emulsified with 1 mL of 5 % 
(w/v) PVA aqueous solution using an IKA UltraTurrax T10 Basic® at 3000 rpm for two minutes, 
resulting in a w/o emulsion. The 5 % (w/v) PVA aqueous solution was added drop-by-drop to the w/o 
emulsion. This emulsion was then added dropwise to 40 mL of 2.5 % (w/v) PVA aqueous solution, 
0.75 % (w/v) CH aqueous solution or 0.75 % (w/v) ALG aqueous solution and emulsified during 5 
minutes using a Yellowline DI25 Basic UltraTurrax® at 9500 rpm, resulting in a w/o/w emulsion. 
Formulations were then placed under magnetic stirring for 3 h at room temperature, to allow the 
organic solvent (or DCM) evaporation. PLGA MPs were collected by centrifugation at 6240 × g 
during 20 minutes at 4 C (Centrifuge Mega Fuge 1.0R Heraeus) and washed three times with 20 mL 
of ultrapure water to remove the excess of PVA (or surfactant). PLGA MPs were finally resuspended 
in 5 mL of ultrapure water. 
Coumarin-6-loaded MPs (PLGA-C6 MPs) were formulated using the same protocol and adding 
the mentioned solutions of coumarin-6 at different concentrations during the formulation procedure. A 
5.5610-4 M coumarin-6 stock solution was prepared in ethanol and different volumes (51, 128, 257, 
514 or 1284 L) were added to the oil phase. DCM was added to complete the 5 mL of the oil phase 
and 250 mg of PLGA were then dissolved in this organic phase. PLGA-C6 MPs were washed as 
mentioned above to remove the excess of PVA and the non-entrapped coumarin-6.  
 
 
  Formulation Concentration of coumarin-6 (g/mg)  External Phase 
  
N
o
n
-s
u
rf
a
ce
 
m
o
d
if
ie
d
 M
P
s 
PLGA PVA 0.00 
 
2.5 % (w/v) PVA 
 
PLGA PVA-C6-1 0.04 
PLGA PVA-C6-2 0.10 
PLGA PVA-C6-3 0.20 
PLGA PVA-C6-4 0.40 
PLGA PVA-C6-5 1.00 
C
H
 s
u
rf
a
ce
 
m
o
d
if
ie
d
 M
P
s 
PLGA CH 0.00  
PLGA CH-C6-1 0.04 
 
0.75 % (w/v) CH 
 
PLGA CH-C6-2 0.10 
PLGA CH-C6-3 0.20 
PLGA CH-C6-4 0.40 
PLGA CH-C6-5 1.00 
A
L
G
 s
u
rf
a
ce
 
m
o
d
if
ie
d
 M
P
s 
PLGA ALG 0.00  
PLGA ALG-C6-1 0.04 
 
0.75 % (w/v) ALG 
 
PLGA ALG-C6-2 0.10 
PLGA ALG-C6-3 0.20 
PLGA ALG-C6-4 0.40 
PLGA ALG-C6-5 1.00 
Table 4.1 Composition of the plain, CH surface modified MPs and ALG surface modified MPs. 
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4.2.3  Physicochemical Characterization of the surface-modified 
microparticles 
4.2.3.1 Microparticle size and ZP analyses 
MP size parameters (D10%, D50%, D90%) were measured by laser diffraction using a Malvern 
Mastersizer Hydro 2000S. MP suspensions were diluted to 1:10 in ultrapure water, the obscuration 
window was set at 10-15 % and the target value was 12 %. Before each measurement, the device was 
washed with ultrapure water to attain a laser beam intensity above 80 %. The background was 
measured when the light energy was fewer than 60 %, fewer than 20 % and approximately 0 to 
detectors 0, 20 and 30, respectively. The size parameters represent an average of 6 measurements. MP 
sizes are represented as MP size distributions by volume and the span, which is a calculation of the 
width of the distribution of the volume in relation to the median diameter, was calculated by the 
expression 
         
    
  Equation 4.2 
Results are expressed as the mean of three independent experiments measured in triplicate.  
The MPs’ surface charge was analyzed through ZP measurement by Laser Doppler 
Electrophoresis at 25 C using a Malvern Zetasizer Nano ZS equipment. MP suspensions were diluted 
to 1:4 in ultrapure water (pH=5.7). Approximately 0.8 mL were used to fill the clear disponsible 
capillary zeta cell (DTS060C). The ZP data represents an average of a triplicate measurement of 50 
rounds with an equilibration time of 30 seconds. Results are expressed as the mean of three 
independent experiments measured in triplicate.  
 
4.2.3.2 Confocal Microscopy 
The size and shape of coumarin-6-loaded PLGA MPs containing 0.2 g/mg of coumarin-6 
was evaluated by confocal microscopy imaging. Each batch of MP suspension (initial concentration: 
50 mg/mL) was diluted to 1:200 in ultrapure water (pH=5.7). The final concentration of MPs was 0.25 
mg/mL. Samples were then analyzed using a Leica TSC SP5 (Leica Microsystems CMS GmbH, 
Mannheim, Germany) inverted microscope (DMI6000) with a 63x water (1.2 numerical aperture) 
apochromatic objective. The excitation of coumarin-6 fluorophore was performed through the 458 nm 
line of an Ar
+
 laser beam and the emission collected beetween 480-530 nm wavelenghts. The confocal 
sections had a thickness bellow 0.5 μm. Three-dimensional (3D) projections were obtained using a 
galvanometric motor stage and processed using the Leica Application Suite-Advanced Fluorescence 
Software. 
 
4.2.3.3 Coumarin-6 loading analysis 
The Entrapment Efficiency (E.E., %) and the Loading Capacity (L.C., g/mg) of coumarin-6 
were determined through direct quantification, by absorption spectroscopy using a Hitachi U-2001 
UV/Vis Spectrometer. For each batch of coumarin-6-loaded PLGA MPs containing 0.2 g/mg of 
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coumarin-6, MPs were collected by centrifugation at 6240 × g during 20 minutes at 4C, using the 
Centrifuge Mega Fuge 1.0R Heraeus. The supernatant was removed and the pellet dissolved in DCM. 
However the complete dissolution was not immediately attained once two different phases were 
observed. Therefore, the pellet in DCM was placed at strong magnetic stirring for 2 h to obtain a 
solution of coumarin-6 and PLGA polymer. The measurements were done in 1 cm quartz absorption 
cuvettes and the concentration was determined by measuring the absorption at 455 nm and using non-
fluorescent MPs dissolved in DCM as blank. The absorption calibration curve was prepared using 
coumarin-6 solutions in DCM at different known concentrations. Using the Beer-Lambert law, the 
slope of the calibration curve was obtained and the  (coumarin-6 λmax=455 nm, DCM)=55.610
3 
M
-
1
cm
-1 
calculated. The E.E. (%) and the L.C. (g/mg) for coumarin-6 were determined using the follows 
equations: 
 
    ( )  
                             
                           
          Equation 4.3 
    (      )   
                         
                      
                  Equation 4.4 
 
4.2.3.4 Statistical Analysis 
All experimental results are expressed as mean ± standard deviation (SD). Two-way ANOVA 
and Bonferroni’s post test were performed in order to demonstrate statistical differences in size and ZP 
data. One-way ANOVA and Tukey’s post test were performed in order to demonstrate statistical 
differences in E.E. (%) and L.C. (g/mg) data. All the statistical analysis was made using the Graph 
Pad software (version 5.02) for Windows®. Differences were considered statistically significant at p < 
0.05. 
 
4.2.4  Spectral characterization of coumarin-6 
For each batch of PLGA-C6 MPs, five dilutions (1:100, 1:125, 1:200, 1:250 and 1:500) were 
prepared in ultrapure water (pH=5.7) and achieving the following final concentrations of coumarin-6-
loaded PLGA MPs: 0.50, 0.40, 0.25, 0.20 and 0.10 mg/mL. 
Steady-state fluorescence measurements were performed at room temperature (23 C) in a 
SLM Aminco 8100 series 2 spectrofluorimeter or in a Hitachi F-2000 Spectrofluorimeter, using 0.5 
cm or 1.0 cm quartz cuvettes. Under the experimental conditions employed in this study the excitation 
and emission maxima wavelengths (ex/em) were determined to be 465 nm and 500 nm, respectively. 
However, due to partial overlay of the emission and excitation spectra and in order to collect the whole 
excitation and emission spectra of the probe, measurements were performed setting the emission 
wavelength to 510 nm during the acquisition of the excitation spectra, while the excitation wavelength 
was set to 445 nm during the acquisition of the emission spectra.  
The steady-state anisotropy, < r >, was calculated according to the equation: 
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      Equation 4.5 
Where IVV is the emission intensity measured parallelarly to the vertical polarized excitation, 
IVH is the emission intensity measured perpendicularly and G is a correction factor calculated by the 
ratio between the emission intensity measured parallelarly and perpendicularly to the horizontal 
polarized excitation (91). Fluorescence anisotropy measurements were performed using 
ex/em=445/500 nm. An appropriate blank was subtracted from each intensity reading before 
calculation of the anisotropy value. 
 
4.2.5  Giant unilamellar vesicles preparation 
Three different lipid mixtures were prepared: POPC, POPC/DPPC (1:1 mol/mol) and 
POPC/SM/Chol (1:1:1 mol/mol/mol). 
The lipid mixtures containing the adequate amount of lipids, DOPE-biotin (at a 
biotinylated:non-biotinylated lipid ratio of 1:10
6
), Rho-DOPE (at a probe:lipid ratio of 1:500) were 
prepared in glass amber vials. 3 L of each lipid mixture were spread onto the platinum electrodes. 
The solvent was dried in vacuum and the electrodes were placed in 1 mL of 200 mM sucrose solution 
heated at 60 ˚C. GUVs were prepared by electroformation using an alternating electric field of a 
sinusoidal wave of 30 Hz and 0.2 V during 1 h 15 min. Prior to GUVs preparation, the wells of an 8-
well μ-Slide from Ibidi® were coated with avidin at 0.1 mg/mL to facilitate the adhesion of the GUV 
to the plate by the reaction of avidin/biotin (84). The wells were then washed three times with 200 L 
of ultrapure water (pH=5.7) to remove the excess of avidin. GUVs (150 μL) were transferred into the 
wells and 250 μL of glucose were then added to each well. 
 
4.2.6  Impact of the surface properties in the interaction between surface-
modified microparticles and giant unilamellar vesicles  
The interaction between coumarin-6-loaded PLGA MPs and GUVs was evaluated by confocal 
microscopy imaging. Each suspension of coumarin-6-loaded PLGA MPs containing 0.2 µg/mg of 
coumarin-6 was diluted to 1:200 in ultrapure water (final concentration of 0.25 mg/mL, pH=5.7). 50 
L of PLGA MPs were added into the GUVs-containing wells of the 8-well μ-Slide. The excitation of 
coumarin-6 and Rho-DOPE was performed using the 458 and 514 nm lines of an Ar
+
 laser, 
respectively. The emission was collected in the ranges of 480-530 nm and 530-650 nm for coumarin-6 
and Rho-DOPE, respectively. By using the setting ―smart offset‖ set bellow 0.5, the stray light was 
reduced.  The confocal sections with a thickness bellow than 0.5 μm were obtained using a 
galvanometric motor stage. The three-dimensional (3D) projections were obtained using the Leica 
Application Suite-Advanced Fluorescence Software. Confocal microscopy imaging of GUVs 
interacting with MPs was performed during 3 h.  
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A B 
Figure 5.1 Microparticle Size Distribution by Volume. (A) PLGA MPs: PLGA PVA MPs (blue), PLGA CH 
MPS (red) and PLGA ALG MPs (green). (B) PLGA-C6 MPs (labeled with 0.2 m /mg of coumarin-6): PLGA 
PVA-C6-3 MPs (blue), PLGA CH-C6-3 MPS (red) and PLGA ALG-C6-3 MPs (green).  
CHAPTER 5: Results 
5.1  Characterization of the surface-modified MPs 
Surface-modified MPs were characterized in terms of size (D10%, D50%, D90%), span, ZP and shape. 
Values of D10%, D50%, D90% and span are summarized on Table 5.1 according to MP surface 
modification with PVA, CH or ALG and to the coumarin-6 concentration. Histograms of MP size 
distribution in terms of Volume (%) are also represented on Figure 5.1 for plain or non-fluorescent 
MPs (Figure 5.1 A) and coumarin-6-loaded MPs containing 0.2 μg/mL of coumarin-6 (Figure 5.1 B). 
Unloaded and coumarin-6-loaded PLGA MPs presented median size (D50%) values ranging from 
1.4±0.3 m to 3.8±0.2 m and span ranging from 1.1±0.2 to 4.8±1.1 (Table 5.1). Specifically, non-
fluorescent MPs ranged from 2.9±0.3 m and 3.8±0.1 m, being the highest D50% values obtained for 
PLGA PVA MPs and the lowest ones for PLGA ALG MPs. In fact, the differences observed in D50% 
values of MPs were not statistically significant, suggesting that the different surface modifications did 
not have a significant impact on their median size values. Even though, slightly different size 
distribution patterns can be observed on the size distribution histograms for non-fluorescent MPs 
prepared according to the different surface modifications tested (Figure 5.1 A). PLGA PVA MPs 
showed the most homogeneous population in terms of size polydispersity, as can be seen by the 
narrower single peak of the histogram (blue line). PLGA CH MPs (red line) exhibited a slightly wider 
size distribution, with a D50% value of 2.9±0.8 m. PLGA ALG MPs (green line) presented the lowest 
D50% value (2.9±0.3 m) but also the most heterogeneous population, as can be observed by the 
presence of a wide subpopulation ranging from 10 m to 50 μm, approximately.  
Regarding coumarin-6-loaded MPs, the presence of the fluorescent probe at different 
concentrations did not demonstrate a statistically significant impact on D50% values, except for PLGA 
ALG MPs containing 0.4 and 1.0 μg/mL of coumarin-6 (1.4±0.3 μm and 1.7±0.1 μm, respectively) 
that presented a significant (p < 0.01) lower D50% values comparing to MPs containing 0.04 μg/mL 
(3.7±1.2 μm) (Table 5.1). PLGA PVA MPs and PLGA CH MPs did not demonstrate statistically 
significant differences for D50% values regarding the different concentrations of coumarin-6 tested 
(Table 5.1). For PLGA ALG-C6-4 MPs and PLGA ALG-C6-5 MPs, D10% values showed the presence 
of one subpopulation in the nanometer size.  
 
Microparticle Size (m) Microparticle Size (m)
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Table 5.1 Physicochemical characterization of coumarin-6-loaded PLGA Microparticles. Size parameters of unloaded and 
coumarin-6 loaded PLGA PVA MPs, PLGA CH MPs and PLGA ALG MPs are presented as span, D10%, D50% and D90% 
(mean ± SD; N ≥ 3, n = 3). Statistical analysis: two way ANOVA and Bonferroni’s post test. D50% **
a significantly different 
(p < 0.01) comparing to PLGA ALG C6-5. D50% **
b significantly different (p < 0.01) comparing to PLGA ALG C6-4.  
 
In order to study the impact of MP surface charge on the interaction between MPs and 
biomembrane models, three different polymers known to cause alterations on the surface charge of 
particles (24), were used in the formulation process. Surface charge of the different MPs was analyzed 
through the ZP measurement by Laser Doppler Electrophoresis, at 25 C in ultrapure water. As 
expected, PLGA MPs prepared with distinct surface-modifier polymers clearly exhibited different 
surface charges. PLGA CH MPs showed a highly positive surface charge (50.8±2.7 mV). In contrast, 
negative surface charges were displayed for PLGA ALG MPs (-36.8±4.4 mV) and for PLGA PVA 
MPs (-19.6±1.1 mV) (Table 5.2). Surface charges results for non-fluorescent PLGA MPs were 
significantly affected (p < 0.001) by the different surface modifications (PVA, ALG or CH). 
 
  Formulation 
Concentration 
of coumarin-6 
(g/mg)  
Span  D10% (m) D50% (m) D90% (m) 
  
N
o
n
-s
u
rf
a
ce
 m
o
d
if
ie
d
 M
P
s PLGA PVA 0.00 1.3±0.1 2.1±0.1 3.4±0.1 6.9±0.4 
PLGA PVA-C6-1 0.04 1.9±0.3 1.6±0.4 3.5±0.4 8.0±0.1 
PLGA PVA-C6-2 0.10 1.8±0.3 1.5±0.2 3.5±0.4 7.8±0.5 
PLGA PVA-C6-3 0.20 1.5±0.3 1.6±0.2 3.4±0.8 6.5±0.3 
PLGA PVA-C6-4 0.40 3.2±0.4 1.7±0.3 2.8±0.3 10.6±1.9 
PLGA PVA-C6-5 1.00 1.6±0.3 1.8±0.2 3.8±0.2 7.6±0.6 
C
H
 s
u
rf
a
ce
 m
o
d
if
ie
d
 M
P
s PLGA CH 0.00 1.9±0.4 1.4±0.3 2.9±0.8 6.9±1.6 
PLGA CH-C6-1 0.04 1.3±0.0 1.5±0.1 2.6±0.1 4.7±0.2 
PLGA CH-C6-2 0.10 1.1±0.2 1.5±0.1 2.4±0.3 4.3±0.9 
PLGA CH-C6-3 0.20 1.3±0.2 1.5±0.0 2.6±0.2 4.9±0.8 
PLGA CH-C6-4 0.40 2.5±1.0 1.4±0.3 3.5±0.0 9.5±5.2 
PLGA CH-C6-5 1.00 1.9±0.4 1.0±0.1 2.5±1.2 5.8±3.7 
A
L
G
 s
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a
ce
 m
o
d
if
ie
d
 M
P
s PLGA ALG 0.00 3.7±1.9 1.3±0.1 2.9±0.3 12.1±6.5 
PLGA ALG-C6-1 0.04 4.8±1.1 1.6±0.2 3.7±1.2 13.1±9.4 
PLGA ALG-C6-2 0.10 2.7±0.0 1.4±0.1 2.4±0.9 9.4±0.6 
PLGA ALG-C6-3 0.20 2.0±0.2 1.5±0.0 3.0±0.0 7.4±0.7 
PLGA ALG-C6-4 0.40 2.8±0.5 0.1±0.0 1.4±0.3**
a
 6.5±2.0 
PLGA ALG-C6-5 1.00 3.3±0.1 0.1±0.0 1.7±0.1**
b
 5.6±0.2 
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On the other hand, MP loading with coumarin-6 did not change the surface charge of MPs since 
no statistically significant differences were observed regarding the different coumarin-6 concentrations 
tested (p > 0.001) (Table 5.2). PLGA CH-C6 MPs presented highly positive ZP values ranging from 
53.6±4.5 mV to 58.7±3.4 mV and PLGA ALG-C6 MPs showed highly negative ZP values ranging 
from -30.8±2.3 mV to -36.2±3.3 mV. PLGA PVA-C6 MPs also presented negative ZP values ranged 
between -17.8±0.9 mV and -19.9±0.2 mV. Independently of the coumarin-6 concentration used, 
statistical differences were found for the surface charge values of the different surface-modified MPs 
(p < 0.001). 
 
  
 
 
Confocal microscopy was used to qualitatively characterize the size and shape of coumarin-6-
loaded PLGA MPs and also to provide insights on the apparent probe distribution throughout the 
polymeric matrix of MPs. PLGA MPs containing 0.2 g/mg of coumarin-6 were formulated with the 
different surface-modifying polymers (PVA, ALG and CH). MPs were then resuspended in ultrapure 
water and diluted to 1:200 to a final concentration of 0.25 mg/mL. Three-dimensional projections 
represented in Figure 5.2 were obtained from confocal sections. In general, MPs presented a spherical 
shape, as can be seen on confocal images (Figure 5.2). Notwithstanding, some PLGA PVA-C6-3 MPs 
and PLGA ALG-C6-3 appear with a sickle-like shape (Figure 5.2 D and E), probably resulting from 
the collapse of some MPs, apparently those with larger sizes. Since MPs were formulated and 
immediately observed, the results obtained might suggest that these types of MPs are slightly unstable 
under the experimental conditions used. Some MP aggregation was observed for PLGA PVA-C6-3 
  Formulation Concentration of coumarin-6 (g/mg) ZP (mV) 
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PLGA PVA 0.00 -19.6±1.1*** 
PLGA PVA-C6-1 0.04 -19.9±0.2*** 
PLGA PVA-C6-2 0.10 -18.8±2.0*** 
PLGA PVA-C6-3 0.20 -17.8±0.9*** 
PLGA PVA-C6-4 0.40 -19.0±1.1*** 
PLGA PVA-C6-5 1.00 -18.5±0.8*** 
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PLGA CH 0.00 50.8±2.7*** 
PLGA CH-C6-1 0.04 54.0±3.9*** 
PLGA CH-C6-2 0.10 56.9±6.3*** 
PLGA CH-C6-3 0.20 55.1±3.5*** 
PLGA CH-C6-4 0.40 53.6±4.5*** 
PLGA CH-C6-5 1.00 58.7±3.4*** 
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PLGA ALG 0.00 -36.8±4.4*** 
PLGA ALG-C6-1 0.04 -31.9±3.0*** 
PLGA ALG-C6-2 0.10 -36.2±3.3*** 
PLGA ALG-C6-3 0.20 -32.3±1.7*** 
PLGA ALG-C6-4 0.40 -32.5±2.6*** 
PLGA ALG-C6-5 1.00 -30.8±2.3*** 
Table 5.2 Physicochemical characterization of the PLGA MPs. Table shows the Zeta Potential (ZP) of the unloaded and 
coumarin-6 loaded PLGA MPs. Data correspond to mean ± SD (N ≥ 3, n = 3). Statistical analysis: two way ANOVA and 
Bonferroni’s post test. Relative to the same coumarin-6 concentration *** p < 0.001. 
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Figure 5.2 Physichochemical properties of coumarin-6-loaded PLGA MPs with different surface modifications were 
evaluated by confocal microscopy  imaging. Three-dimensional projection images from 0.5 μm confocal slices of PLGA 
MPs labeled with coumarin-6 (green): (A), (D) PLGA PVA-C6-3 MPs, (B) PLGA CH-C6-3 MPs, (C), (E) PLGA ALG-
C6-3 MPs. Representative images of three independent experiments are shown. Scale bars = 10 μm 
 
MPs (as pointed in Figure 5.2 A), which might be related to the surface hydrophobicity conferred by 
the hydrophobic nature of the polymeric matrix of the MPs and consequent instability in aqueous 
suspension. Confocal microscopy images showed that coumarin-6 seems to have a predominant 
uniform distribution as denoted by the dense green color noticed in the majority of the MPs observed. 
However, some of the PLGA PVA-C6-3 MPs (Figure 5.2 A) and PLGA ALG-C6-3 MPs (Figure 5.2   
C, E) displayed small round-like dark areas that might correspond to coumarin-6-free regions.  
5.2  Spectral characterization of coumarin-6 
Coumarins are a family of molecules composed by a fused pyrone and benzene rings, 
presenting the pyrone carbonyl group at position 2 (92,93). Coumarins can exhibit high sensitivity to 
the environment properties such as local polarity, microviscosity and pH (92). They are known to have 
a high fluorescence in the green and blue regions of the spectrum and high quantum yield (92,94). 3-
(2’-benzothiazolyl)-7-N,N-diethylaminocoumarin, also named coumarin-6, is a good example of this 
type of coumarins. The absorption and fluorescence spectra of coumarin-6 display a solvatochromic 
behaviour to the red region for increasing values of solvent polarity. To characterize the photophysical 
properties and localization of coumarin-6 into polymeric matrix of the PLGA-C6 MPs, the absorption 
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Figure 5.3 Coumarin-6 absorption spectra and calibration curve in stock solutions prepared in DCM and ethanol. 
(A) Coumarin-6 absorption spectra and (B) Calibration curve both obtained by the different solutions prepared 
from the coumarin-6 stock solution in DCM (in triplicate). Normalized absorption spectra of the different solutions 
prepared from (C) the coumarin-6 stock solution in DCM (detail of the two ranges of maximal absorption) and (D) 
coumarin-6 stock solution in ethanol. Concentrations of each solution of coumarin-6:  1.85 M (light blue), 3.7 
M (orange), 5.56 M (light green), 7.41M (green), 9.26 M (dark green), 11.1 M (purple). Data correspond to 
N ≥ 3, n = 3. 
C D 
A B 
and fluorescence spectra of coumarin-6 were performed. In fact, these methods are excellent tools to 
access the impact of the microenvironment on the electronic states of the molecules (95). For each 
batch of PLGA-C6 MPs, the suspensions were diluted to 1:100, 1:125, 1:200, 1:250 and 1:500 (final 
concentration of PLGA in the suspensions: 0.50, 0.40, 0.25, 0.20 and 0.10 mg/mL, respectively) in 
ultrapure water, and the photophysical parameters of coumarin-6 were evaluated. 
 
5.2.1 Spectral characterization of coumarin-6 – the stock solutions 
 According to the formulation process employed, PLGA was dissolved in DCM to form the oil 
phase. Coumarin-6 stock solution was also prepared in DCM and the photophysical properties of the 
probe in this organic solvent were characterized. Figure 5.3 A and C shows the absorption spectra for 
coumarin-6 solutions prepared in DCM, at different concentrations. As observed, the absorption 
occurs in the range of 400-490 nm, being observed two wavelength ranges with absorption maxima at 
445-448 nm and 455-463 nm. These results suggest that more than one electronic transition is 
occurring due to some aggregation in coumarin-6 chemical structure. This phenomenon can be 
explained by the presence of certain sites in coumarin-6 that are interacting with DCM at different 
strengths. However, literature data suggest that coumarin-6 presents a maximum of absorption at 455 
nm in DCM and no aggregation behavior has been reported (93).  
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Figure 5.4 Coumarin-6 excitation and emission spectra in PLGA-C6 MPs labeled with 0.20 g/mg of coumarin-6 for the different 
concentrations of MPs in suspension. Excitation and emission spectra of (A) PLGA PVA-C6 MPs, (B) PLGA CH-C6 MPs, and (C) 
PLGA ALG-C6 MPs and correspondent normalized excitation and emission spectra (D,E,F) . Data for the concentrations of PLGA in 
suspension 0.10 mg/mL, 0.20 mg/mL, 0.25 mg/mL, 0.40 mg/ml and 0.50 mg/mL are shown in blue, red, green, purple and light blue. 
Data correspond to N = 1, n = 1. F.I. Measurements were performed setting λem=510 nm during the acquisition of the excitation 
spectra and λex = 445 nm during the acquisition of the emission spectra. Fluorescence Intensity (a.u). 
E 
To avoid the use of a stock solution that could present coumarin-6 aggregates, a new stock 
solution was prepared using ethanol as solvent (Figure 5.3 D). Coumarin-6 in ethanol presents an 
absorption in the range of  390 - 490 nm and an absorption maximum at 458 nm, in agreement with 
previous studies (93). According to the spectral results obtained, it can be inferred that coumarin-6 is 
more soluble in ethanol than DCM. Since no aggregated species seemed to be present in this stock 
solution, coumarin-6 in ethanol was used during the formulation process of the PLGA-C6 MPs.  
 
5.2.2 Spectral characterization of coumarin-6-loaded MPs 
To characterize coumarin-6-loaded PLGA MPs, UV-Vis and fluorescence spectroscopy were 
initially employed. However, it was not possible to address the extent of incorporation of coumarin-6 
into MPs using UV-Vis spectroscopy due to the lower sensitivity of this tecnhique (data not shown). 
To determine the parameters that resulted in optimal formulation conditions of coumarin-6-loaded 
PLGA MPs, two types of studies were performed. In the first set of experiments, the concentration of 
coumarin-6 loaded into MPs was kept constant and the concentration of MPs in suspension was 
varied. In the second set of experiments, the influence of coumarin-6 concentration was studied for 
each concentration of MPs in suspension. These studies allowed to determine the best probe-to-
polymer ratio to be used in the formulation process. 
Figure 5.4 shows the excitation and emission spectra for the different PLGA-C6 MPs 
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Figure 5.5 Coumarin-6 and emission spectra in PLGA-C6 MPs labeled with 0.20 
g/mg of coumarin-6 for MPs concentration 0.25 mg/mL, (A) non-normalized and 
(B) normalized. Data for PLGA PVA-C6-3 MPs, PLGA CH-C6-3 and PLGA ALG-
C6-3 MPs is shown in blue, red and green (respectively). Data correspond to N = 1, 
n = 1. Measurements were performed setting λex = 445 nm during the acquisition of 
the emission spectra. F.I. Fluorescence Intensity (a.u.).   
 
A B 
containing 0.2 g/mg of coumarin-6. In Figure 5.4 B and C the left YY axis represents the excitation 
and the right YY axis the emission.  Excitation and emission spectra for PLGA MPs labeled with 0.04, 
0.1, 0.4 and 1.00 g/mg of coumarin-6 are shown in Annex 1. Overall data shows that increasing the 
MP concentration in the suspension results in increased fluorescence intensities (Figure 5.4 A-C). 
However, no spectral alterations were observed (Figure 5.4 D-F), displaying that changes in MP 
suspension content do not affect the partition of coumarin-6 between the hydrophobic polymeric 
matrix, MP surface and aqueous environment. 
Comparison between the emission spectra of coumarin-6 when loaded in the different MPs 
shows that fluorescence intensity is lower in PLGA CH-C6-3 MPs and quite similar for the remaining 
ones (Figure 5.5 A). Moreover, no spectral alterations were detected when coumarin-6 was loaded in 
the different MPs suggesting that under these conditions the probe is essentially located in the 
hydrophobic polymeric matrix (Figure 5.5 B). 
 
To further characterize the different coumarin-6-loaded PLGA MPs, the variation of the 
fluorescence intensity maximum of coumarin-6 as a function of the concentration of  PLGA-C6 MPs 
in suspension was analysed (Figure 5.6). As it would be anticipated, an increase in the fluorescence 
intensity maximum is observed upon increasing the concentration of the PLGA-C6 MPs, 
independently of their surface modification. It would be expected that for the same concentration of 
coumarin-6 used to label PLGA-C6 MPs, the fluorescence intensity maximum of the probe would 
change linearly with the concentration of PLGA-C6 MPs. This fact can be mainly confirmed for 
PLGA PVA-C6 MPs that present an almost linear trend of variation of the fluorescence intensity for 
all the concentrations of coumarin-6 studied. However, the variation is not perfectly linear for PLGA 
PVA-C6-3/4/5 MPs (0.2, 0.4 and 1.0 g/mg of coumarin-6). For PLGA CH-C6 MPs and PLGA-ALG-
C6 MPs, the variation in the fluorescence intensity maximum is also close to linear, but the data are 
more scattered. This might be mainly due to experimental errors during the dilution of the samples. 
Indeed, the PLGA-C6 MPs have a strong tendency to sediment and form non-homogenous solutions. 
Differences in the redispersion of the PLGA-C6 MPs could account for this scattered variation. 
Nonetheless, because the general trend is close to linear, one can assume that no significant 
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Figure 5.6 Variation of coumarin-6 fluorescence intensity maximum as a function of MPs concentration in the 
suspension in (A) PLGA PVA-C6 MPs, (B) PLGA CH-C6 MPs and (C) PLGA ALG-C6 MPs. Data for coumarin-6 
concentration 0.04 g/mg, 0.10 g/mg, 0.20 g/mg, 0.40 g/mg and 1.00 g/mg is shown in blue, red, green, purple 
and light blue, respectively. Data correspond to N = 1, n = 1. F.I. MAX, Fluorescence Intensity Maximum (a.u).  
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Figure 5.7 Variation of coumarin-6 fluorescence intensity maximum as a function of 
MPs concentration in the suspension. PLGA MPs were loaded with (A) 0.2 and (B) 
0.4 µg coumarin-6/mg of PLGA. Data for PLGA PVA, PLGA CH and PLGA ALG 
MPs are shown in blue, red and green, respectively. Data correspond to N = 1, n = 1. 
F.I. MAX, Fluorescence Intensity Maximum (a.u). 
A B 
differences in the partition of the coumarin-6 between the polymeric medium and the aqueous solution 
are taking place upon dilution of the samples. It should be noted that for the higher coumarin-6 
concentration, saturation of fluorescence intensity maximum is observed. In fact, fluorescence 
quantum yield of coumarin-6 in hydrophobic mediums such as DCM is 0.94 and in water is 0.03 (93). 
Thus, the saturaded behaviour could be explained by some probe adsorption onto the MPs surface or 
even in water, where the quantum yieald is lower.  
 
 
Comparison of the fluorescence properties of coumarin when loaded in different MPs showed 
that fluorescence intensity maximum increases with the increase of the concentration of the PLGA-
C6-3/4 MPs suspension in a linear manner (Figure 5.7). Actually, for PLGA-C6 MPs labeled with 0.4 
g/mg of coumarin-6, there is a direct correlation between the increase of fluorescence intensity 
maximum and the concentration of MPs. Results further show differences upon changing the distinct 
surface-modifier polymers during MPs formulation. In fact, fluorescence intensity maximum values 
are lower for CH surface-modified MPs comparing with PVA and ALG formulations. In fact, 
fluorescence intensity maximum values of PVA and ALG formulations are generally similar. 
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Figure 5.8 Coumarin-6 normalized spectra in (A) PLGA PVA-C6 MPs, (B) PLGA-CH-C6 MPs and (C) PLGA-ALG-C6 
MPs labeled with 0.04 g/mg (blue), 0.10 g/mg (red), 0.20 g/mg (green), 0.40 g/mg (purple) and 1.00 g/mg (light 
blue) of coumarin-6. Variation of em max in (D) PLGA PVA-C6 MPs, (E) PLGA-CH-C6 MPs, and (F) PLGA-ALG-C6 
MPs as a function of coumarin-6 concentration. The concentration of the MPs in the suspension is 0.25 mg/mL for all 
panels. Data correspond to N = 1, n = 1. Measurements were performed setting λex = 445 nm during the acquisition of the 
emission spectra. F.I. Fluorescence Intensity (a.u.). 
A B C 
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Figure 5.8 A-C shows the emission spectra of coumarin-6 in PLGA-C6 MPs suspension with 
0.25 mg/mL of PLGA concentration. Additional spectra obtained for PLGA-C6 MPs suspensions with 
MPs concentrations of 0.50, 0.40, 0.20 and 0.10 mg/mL are shown in Annex 2. Results demonstrate a 
red shift in the probe emission for increasing concentrations of coumarin-6. This behaviour is 
observed in the three different formulations studied (PVA, CH and ALG). Indeed, an ap. 15 nm shift 
(from 485 to 500 nm) in the maximum emission wavelenght is also observed when coumarin-6 
concentration increases from 0.04 to 1.00 g/mg, regardless of MP composition (Figure 5.8 D-F). 
Additional spectra obtained for PLGA-C6 MP suspensions at different concentrations of 0.50, 0.40, 
0.20 and 0.10 mg/mL are presented in Annex 3. These results suggest that coumarin-6 is 
predominantly localized in the polymeric matrix. However, for higher probe concentrations, the 
increase of em might be explained by an exposure of the probe in the MPs surface or by increase of 
non-encapsulated molecules that remains in the water.  
 
Figure 5.9 shows the variation of the fluorescence intensity maximum as a function of the 
concentration of coumarin-6 used to label PLGA-C6 MPs. Data shows that the fluorescence intensity 
maximum increases almost linearly with the concentration of coumarin-6, except for lower probe 
concentrations in PLGA PVA-C6 MPs and PLGA ALG-C6 MPs. Experimental errors and the strong 
tendency to sediment may account for this variation. 
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Figure 5.9 Variation of the coumarin-6 fluorescence intensity maximum as a function of probe concentration in (A) PLGA 
PVA-C6 MPs, (B) PLGA CH-C6 MPs and (C) PLGA ALG-C6 MPs. Data for the concentration of PLGA in suspension 
0.10 mg/mL, 0.20 mg/ml, 0.25 mg/mL, 0.40 mg/mL and 0.50 mg/mL are shown in blue, red, green, purple and light blue. 
Data correspond to N = 1, n = 1. F.I. MAX, Fluorescence Intensity Maximum (a.u).  
 
A B C
 
To further infer about the localization of coumarin-6 in the hydrophobic polymeric matrix of 
PLGA, the steady-state anisotropy of the probe was measured (Figure 5.10). Significant differences 
were observed upon changing the concentration of the coumarin-6 (Figure 5.10 A-C). For lower 
coumarin-6 concentrations the anisotropy is very high, suggesting that the probe is highly restricted, 
most likely within the polymeric matrix of PLGA MPs. When the concentration of coumarin-6 
Figure 5.10 Variation of coumarin-6 anisotropy as a function of MPs concentration in suspension (A-C, E-F) or 
coumarin-6 concentration (D). (A) PLGA PVA-C6 MPs, (B) PLGA CH-C6 MPs and (C) PLGA ALG-C6 MPs were 
loaded with 0.04 g/mg (blue), 0.10 g/mg (red), 0.20 g/mg (green), 0.40 g/mg (purple) and 1.00 g/mg (light blue). 
In (D) the concentration of the MPs suspension is 0.25 µg/mL. PLGA PVA MPs (blue), PLGA CH MPs (red) and PLGA 
ALG MPs (green) were loaded with (E) 0.20 g/mg and (F) 0.40 g/mg of coumarin-6. Data correspond to N = 1, n = 1.   
 
A B
A 
C
D E
A 
F
 35 
 
increases a decrease in its fluorescence anisotropy is observed, probably due to a change in the 
environment of the probe. This might result from the exposure of the probe at the surface of the 
PLGA-C6 MPs, or even due to an increase in the population of the probe that is not encapsulated and 
remains in the aqueous environment. Figure 5.10 D shows the variation of the anisotropy as a function 
of the concentration of coumarin-6 ([PLGA]=0.25 mg/ml) for all the formulations. Figure 5.10 E-F 
shows the anisotropy in PLGA PVA-C6-3/4 MPs, PLGA CH-C6 MPs-3/4 and PLGA ALG-C6-3/4 
MPs (labeled with 0.20 and 0.40 g/mg of coumarin-6) as function of MP concentration. Overall, data 
suggest that no significant variation in coumarin-6 anisotropy was observed independently of MP 
composition.  
 
5.3  Quantification of the Coumarin-6 entrappment  
The ability of surface-modified MPs to entrap coumarin-6 was determined by direct method. 
To each batch of PLGA MPs containing 0.2 µg/mg of coumarin-6, the amount of entrapped probe was 
obtained through the dissolution of MPs in DCM and quantified by absorbance spectroscopy at 455 
nm (Table 5.3). Results revealed that all the three types of surface-modified PLGA MPs are able to 
entrap the probe, although in different extensions (Table 5.3). PLGA PVA-C6-3 MPs showed the 
highest capacity to entrap the fluorescent probe, presenting E.E. and L.C. values around 47 % and 24 
μg of coumarin-6 per mg of polymer, respectively. PLGA ALG-C6-3 MPs demonstrated a slightly 
lower E.E. % of 40 % and L.C. of 20 μg/mg. On the other hand, the ability of PLGA CH-C6-3 MPs to 
entrap the probe demonstrated to be significantly different from the other formulations (p < 0.001), 
presenting the lowest E.E. % of 9 % and a L.C. of 5 μg/mg. In fact, spectroscopy data (Figure 5.7 A) 
corroborates the E.E. and L.C. results showing that PLGA CH-C6 MPs displayed always the lowest 
fluorescence intensity maximum values.  Despite the significant differences obtained for the 
entrapment ability of the different types of MPs, the direct method to quantify the amount of 
coumarin-6 entrapped should be improved by using different ratios of DCM:ethanol to dissolve the 
pellet in order to achieve the best proportion to solubilize coumarin-6. As demonstrated by spectral 
results (Figure 5.3 C), coumarin-6 form aggregates in DCM which clearly affect the method used to 
quantify the probe entrappment.  
Alternative concentrations of coumarin-6 and consequently highest values for E.E. % and L.C. 
(μg/mg) were not explored once the main goal of producing fluorescent carriers to study the 
interaction between MPs and membrane models was achieved. Overall, independently from the 
loading values obtained, the entrapment of coumarin-6 into MPs would be considered successful once 
fluorescent MPs could be clearly visualized by confocal microscopy, with sufficient fluorescence 
intensity (Figure 5.2).  
 Table 5.3 Entrapment Efficiency (E.E. %) and Loading Capacity (μg/mg) of coumarin-6 used at an initial concentration 0.2 
μg/ml to formulate surface-modified PLGA MPs with PVA (PLGA PVA-C6-3 MPs), CH (PLGA CH-C6-3 MPs) and ALG 
(PLGA ALG-C6-3 MPs) (mean ± SD; N = 3, n = 3). Statistical analysis: one way ANOVA and Tukey’s post test. E.E and 
L.C., relative to the same coumarin-6 concentration *** p < 0.001. 
Formulation Concentration of 
coumarin-6 (μg/mg) 
Efficiency of 
Entrapment, E.E. (%) 
Loading Capacity,  
L.C. (g/mg) 
PLGA PVA-C6-3 0.2 47.4 ± 8.6 9.5E-02 ± 1.7E-02 
PLGA CH-C6-3 0.2  9.5±5.4*** 1.9E-02 ± 1.1E-02*** 
PLGA ALG-C6-3 0.2 39.6±7.9 7.9E-02 ± 1.6E-02 
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5.4  MPs-membrane interaction: impact of MPs surface properties 
Confocal microscopy was used to study the interaction between PLGA MPs labeled with 0.2 
g/mg of coumarin-6 and GUVs containing different lipid compositions. Three different lipid 
mixtures were used to prepare GUVs: POPC, POPC/DPPC (1:1 mol/mol) and POPC/SM/Chol (1:1:1 
mol/mol/mol). GUVs were labeled with Rho-DOPE, allowing the identification of the phase 
composition of mixtures. Rhodamine-based probes, especially Rhodamine-labeled lipids as 
Rhodamine-DOPE, have been generally used in fusion assays and in the study of membrane lateral 
organization (89). Moreover, this probe has been widely used to study the properties of mixtures 
displaying gel-fluid phase separations and ld-lo phase coexistence (89). It is known that Rhodamine-
based probes are excluded from the lo and gel phases and incorporated into the ld phase, in GUVs (96). 
Thus, the bright areas correspond to the fluid phases and the dark areas correspond to gel and lo phases. 
More specifically, the shape of the domain allows to distinguish the gel phase from the lo phase. 
Studies have also shown that gel domains display dendritic/tubular shapes while lo domains present 
circular shapes (66,84). GUVs obtained by electroformation displayed a nonhomogeneous size 
distribution ranging from 15 to 30 m. Regarding the phase properties of the lipid mixtures (Figure 
25), Rho-DOPE displays a homogeneous distribution along the entire POPC vesicles, being present 
only the fluid phase (Figure 5.11 A-C). In Figure 5.11 D-F, GUVs exhibit fluid (bright areas) and gel 
(dark areas) phases, which according to the POPC/DPPC phase diagram, for a 1:1 mol/mol 
composition, was an expected result. In Figure 5.11 H-I it was possible to observe POPC/SM/Chol 
GUVs displaying fluid-fluid separation, revealed by the presence of bright areas (ld phase), and also 
some dark areas that are thought to be lo phase. On the lo phase, the morphology of the domain can be 
considered as circular. However, results from Figure 5.11 J show that some POPC/SM/Chol (1:1:1 
mol/mol/mol) GUVs also display fluid-gel phase separations revealed by the tubular morphology of 
the domain. This phenomenon can be explained by the improper addition of lipids during the 
preparation, leading to a different lipid proportion from 1:1:1 and some degree of heterogeneity of the 
GUV population in terms of lipid phases. 
Concerning the study of MPs-membrane interaction, the results suggest that regardeless of the 
MPs composition, no specific MPs-membrane interactions occur with fluid homogenous POPC GUVs 
as shown by the absence of MPs internalization and/or overlay with the lipid bilayer (Figure 5.11 A-
C). In contrast, for lipid mixtures displaying gel-fluid phases separation a clear internalization of MPs 
composed of CH and ALG was observed (Figure 5.11 E,F). The analysis of the 3D projection images 
and confocal slices (Figure 5.11 E,F) further suggests that MPs internalization occurs through 
interaction with gel domains and interface of gel-fluid phase. Moreover, the results further suggest that 
MPs surface modified with CH were also able to interact with POPC/SM/Chol mixtures, likely 
through contact with fluid ordered domains (Figure 5.11 H). 
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Figure 5.11 Confocal Microscopy images of GUVs labeled with Rho-DOPE (red), and PLGA-C6 MPs labeled with a 
concentration of 0.2 µg/mg of coumarin-6 (green). The concentration of the MPs in the suspension is 0.25 mg/mL for all 
panels. GUVs are composed by the following lipid mixtures: (A-C) POPC, (D-F) POPC/DPPC (1:1 mol/mol) and (G-J) 
POPC/SM/Chol (1:1:1 mol/mol/mol). Data for PLGA PVA-C6-3 MPs, PLGA CH-C6-3 MPs and PLGA ALG-C6-3 MPs 
are shown in (A,D,G), (B,E,H) and (C,F,I,J), respectively. In (E) is visible de detail of the confocal section which 
demonstrated that the MP is inside the GUV. Representative images of three independent experiments are shown. Scale 
bars = 10 μm.  
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CHAPTER 6: Discussion 
 
Challenges on modern drug delivery are focused on the development of the so called ―smart‖ 
and more effective preventive and/or therapeutic strategies (97). Nano and micro drug delivery 
systems have been explored as promising approaches for therapeutic strategies due to its ability to 
protect the therapeutic entity from proteolytic degradation in biological environment, enhance the 
targeted delivery to specific cells and improve drug bioactivity, minimizing side effects (6). Despite 
the high number of nano and micro particulate systems under research, there is still a lack of 
knowledge on the kinetics of these systems at the cellular level and how they interact with cell 
membranes. Recent studies have suggested that a thorough knowledge of the physicochemical features 
essential for the interaction between drug delivery systems and cells will allow the design of more 
effective and safe carriers (4–6). Accordingly, the study of the interaction of nano/micro drug delivery 
systems with cell membranes and membrane model systems has become an important research line 
(1,4,6,42,43,85). On the other hand, studies on cell membranes and membrane model systems have 
shown that biomembranes are functionally and structurally highly compartmentalized and their lipids 
have an active role on the cellular homeostasis (63–65). However, there is a lack of knowledge on how 
biomembrane properties influence the interactions with nano and micro systems. Exploiting these gaps 
by acquiring a deep expertise in different but complementary areas as nanotechnology, pharmaceutical 
technology, chemistry and biophysics will improve the success rate of the therapeutic entities that 
reaches the target site and also modulate the extent of undesirable effects (97). 
 This project aimed to develop biodegradable and biocompatible surface-modified PLGA 
microparticulate systems in order to evaluate the effect of their surface charge in the interaction with 
membrane model systems. Accordingly, PLGA MPs were prepared using the surface-modifier 
polymers CH and ALG, labeled with a fluorescent probe and physicochemically characterized. A 
thorough spectral study of the probe in its free form and entrapped into PLGA MPs was performed. 
Membrane model systems, more specifically GUVs, were also produced and used to monitor the 
possible interactions with PLGA MPs and to study the impact of different MP surface modifications 
on those interactions, using confocal microscopy. 
 
6.1  Physicochemical characterization of the surface-modified 
microparticles and coumarin-6 spectral characterization 
In vitro and in vivo MP behaviour depends on several physicochemical characteristics 
including size distribution, surface charge, hydrophobicity, chemical composition and morphology 
(48,50,54). Accordingly, PLGA MPs were characterized for their physicochemical properties mainly 
surface charge, size and shape. 
 The median sizes of unloaded and coumarin-6-loaded PLGA MPs ranged between 1.4±0.3 to 
3.8±0.2 m (Table 5.1). The size range obtained can be considered satisfactory to visualize MP under 
the confocal microscope once the minimum size of 200 nm has been reported (98). In fact, the 
differences observed in D50% values of unloaded and coumarin-6-loaded PLGA MPs were mainly not 
statistically significant demonstrating that the different surface modifications and also the coumarin-6 
loading did not have a significant impact on their median size values. Additionally, D10% values for 
PLGA CH-C6-4 MPs, PLGA ALG-C6-4 MPs and PLGA ALG-C6-5 MPs demonstrated the presence 
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of one subpopulation in the nanometer size range. For PLGA ALG-C6-3 MPs, Figure 5.1 B 
demonstrated a subpopulation in micrometer size range. The origin of this subpopulation can be 
explained by different factors such as MP aggregation, insufficient solvent evaporation time and 
inconstant stirring during emulsion steps. In fact, the mechanic agitation of the homogenizer used was 
not completely constant. The homogenizer used (Ultraturrax) is a rotor-stator system composed of 
coaxial intermeshing rings with radial openings. During Ultraturrax homogenization, the fluid enters 
into the system and is accelerated and decelerated multiple times (99). Actually, during the mechanic 
agitation there is some air incorporation and foam formation, leading to loss of the stabilizer surfactant 
agent. Another factor that causes subpopulations is the drop-by-drop addition of the first aqueous 
phase to the oil phase or the first w/o emulsion to the external phase (100). However, while operator 
gets more experient, this addition becomes automatic and variability that can origin these sub 
population decreases. Therefore, adding drop-by-drop will not be a direct cause for these 
subpopulations. 
Analyzing the dispersity, the span results of unloaded and coumarin-6-loaded PLGA MPs 
ranged from 1.1±0.2 to 4.8±1.1 (Table 5.1). Ito et al. reported that PLGA MPs prepared by the 
emulsion solvent method with spans lower than 1 are homogeneous populations (101). Accordingly, 
MP populations under study can be considered heterogeneous being this behavior independent of 
surface modification and probe loading. Despite the absence of flocculation phenomenon during the 
formulation process that suggests a stable formulation, the span values and also the D10% demonstrated 
that MPs aggregate. Consequently, the studied MPs can be considered unstable.  
Confocal results obtained were able to corroborate laser diffraction results. Confocal images 
(Figure 5.2) showed aggregated coumarin-6-loaded PLGA MPs with high size dispersion. Confocal 
studies also revealed the instability of coumarin-6-loaded PLGA PVA MPs and coumarin-6-loaded 
PLGA ALG MPs, which tend to collapse forming sickle-like shapes. Doshi et al. described the 
production of sickle-like shaped PLGA MPs through the shape variation of spherical PLGA MPs by 
their incubation with 2-propanol (102). Actually, the study demonstrated that the partial fluidization of 
PLGA caused by 2-propanol might induce MP collapse. Similarly, the incomplete DCM evaporation 
during the formulation of coumarin-6-loaded PLGA PVA MPs and PLGA ALG MPs could also be the 
cause for this phenomenon. Moreover, confocal studies showed a non-homogeneous labelling of 
PLGA PVA-C6-3 MPs and PLGA ALG-C6-3 MPs by coumarin-6 (Figure 5.2). These spots might 
correspond to DCM that was not completely evaporated or even surfactant on the surface resultant 
from unproper surfactant wash. Surprisingly, coumarin-6-loaded PLGA CH-C6 MPs that 
demonstrated the lowest ability to entrap coumarin-6 displayed an homogenous staining.  
Although D50% values did not demonstrated statistically significant differences, the 
formulation of PLGA MPs containing PVA as external surfactant presented the lowest size disparity. 
This finding is in agreement with other studies that demonstrated that PVA allows the production of 
PLGA NPs and MPs with uniform size distribution (15,103,104). Through intra- and/or intermolecular 
interactions with hydrophobic moieties, PVA fits spontaneously the droplet surface forming micelles 
in aqueous media. This phenomenon confers stability to the formulation process by decreasing the free 
energy at the interface between two phases, and avoiding the coalescence and flocculation of the 
emulsion droplets. Accordingly, PVA particles have lower particle sizes and lower polidispersity 
(105). On the other hand, CH and ALG formulations present higher size disparities. This observation 
can be explained by the higher viscosity of external phase of the secondary emulsion conferred by 
both polymers, which results in the formation of large emulsion droplets. In fact, a higher energy is 
needed to form droplets that will become solid MPs after solvent evaporation. Similar facts were 
previously observed in our laboratory (21,105,106). Moreover, the polymers CH and ALG are derived 
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from natural sources and consequently their own polydispersity is high. An alternative strategy to 
decrease the variability and also produce highly positive and negative PLGA MPs would be the 
coating of PLGA surface with cationic and anionic lipids, respectively (42).   
As expected, non-fluorescent and coumarin-6-loaded PLGA MPs prepared with distinct 
surface-modifier polymers presented significantly different (p < 0.001) surface charges (Table 5.2). 
Non-fluorescent and coumarin-6-loaded PLGA MPs containing PVA displayed ZP values ranging 
from -17.8±0.9 to -19.9±0.2 mV. Similar results were obtained in several studies either for non-
labeled or labeled PLGA NPs and MPs (21,103,107,108). Non-fluorescent and coumarin-6-loaded 
PLGA MPs containing CH as surface modifier showed highly positive ZP values range between 
50.8±2.7 and 58.7±3.4 mV. ZP results confirmed the presence of CH on the surface of MPs resultant 
from the linkage between protonated amino groups of CH and carboxylic end groups of PLGA (109). 
Similar surface-modified PLGA MPs prepared by Manca et al. using the emulsion solvent diffusion 
method show ZP values close to 40 mV for the same CH concentration (0.75 % (w/v)) used in this 
study. (110). Non-fluorescent and coumarin-6-loaded PLGA MPs containing ALG displayed a ZP 
ranging from -30.8±2.3 to -36.8±4.4 mV, confirming the adsorption of ALG to the surface. This 
highly negative surface charge is probably attained due to the presence of the ALG carboxyl groups at 
MP surface. Several studies corroborate the ZP results obtained for ALG surface-modified PLGA MPs 
by suggesting that the surface modification with ALG leads to negatively charged carriers. Florindo et 
al. demonstrated that antigen-loaded PLA NPs modified with ALG at the concentration of 0.75 % 
(w/v) exhibited surface charges that ranged from -50.8±2.4 to -50.0±4.5 mV (105), supporting the 
highly negative ZP values obtained for PLGA MPs containing the same amount of surface modifier.   
Contrary to the results obtained for the different surface-modified MPs (p < 0.001), ZP values seems 
to be independent of the coumarin-6 concentration used. Despite the high negative charge of probe at 
pH 5.7 according to its pKa(coumarin-6) = 0.8, previous observations may indicate that coumarin-6 
molecules should be mainly entrapped into polymer matrix not being available in sufficient amount to 
cause significant surface charge variations in coumarin-6-loaded PLGA MPs (111). However, 
significant differences on ZP values would be observed if a sufficient amount of coumarin-6 was 
present on MP surface. The absence of significant ZP differences can be justified by the trace 
concentration of coumarin-6 used during the formulation process comparing to other formulation 
components.        
Although the MP surface modification with CH and ALG has successfully produced positively 
and negatively charged MPs, it was not possible to produce fluorescent or non-fluorescent PLGA PVA 
MPs with neutral surface charge (Table 5.2). Stolnik et al. reported that PLGA NPs without PVA 
coating have highly negative ZP values close to -45 mV due to the exposure of uncapped carboxyl 
groups of PLGA at NP surface   (112). Accordingly, MP surface coating with amphiphilic polymers 
should lead to the reduction of uncapped carboxyl groups decreasing the ZP (107). In fact, it was 
demonstrated that increasing PVA concentration to values close to 5 % (w/v) can originate particles 
with surface charges close to neutrality (103). Thus, neutrality was not achieved for surface-modified 
PVA MPs probably due to the insufficient concentration of 2.5 % (w/v) PVA used. Therefore, a 
possible future strategy to reach this goal can be designed by increasing PVA concentration. An 
alternative approach to obtain particulate carriers with neutral surface charges may also take into 
account the MP surface modification with hydrophilic polymers such as PEG (113). 
ZP measurement depends on the pH and ionic strength of dispersant as well as on temperature. 
ZP was initially measured in phosphate buffer pH 7.4 containing Ca
2+
 and Mg
2+
 (data not shown) to 
mimetize MP behavior at physiological extracellular conditions. However, all formulations presented 
surface charges close to neutrality, which can be explained by the effect of Ca
2+
 and Mg
2+
 cations in 
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the neutralization of negative charged MPs. Attending the main goals of this study to evaluate the 
impact of different surface charges on the interaction between surface-modified MPs and membrane 
model systems, and to predict the behavior of MPs and GUVs, ultrapure water at pH 5.7 was used to 
measure ZP.  In the absence of any ions at pH 5.7, PLGA PVA MPs were slightly more negative, 
PLGA CH MPs were highly positive and PLGA ALG MPs were highly negative (Table 5.2). The 
aforementioned choice can be supported by Sahoo et al. that published the pH effect in PLGA NPs 
coated with PVA at different concentrations of 0.5, 1, 2 and 5 % (w/v) showing that ZP progressively 
changes to positive values at pH < 5 and above that pH attain negative values (103). On the other 
hand, PLGA and ALG are highly negative at physiological pH. Thereby, electrostatic repulsions 
between both polymers will definitely increase the desorption of ALG from MP surface (114). 
Accordingly, ALG desorption from the surface of negatively charged PLGA MPs can be prevented at 
pH 5.7 once PLGA is less negative and ALG is still anionic. A similar phenomenon might occur for 
CH surface-modified MPs since PLGA is highly negative and CH weakly positive at physiological 
pH, promoting CH desorption. Actually, CH is highly positively charged at pH 5.7 whereas at pH 7.4 
it is close to neutrality (115). Consequently, CH desorption from PLGA MP surface will be vestigial at 
pH 5.7 due to the high electrostatic attraction between both polymers. In conclusion, all these 
evidences can explain the neutral ZP values (data not shown) obtained for non-fluorescent and 
fluorescent surface-modified PLGA MPs, at physiological pH.  
 Analysis of the fluorescence behavior of coumarin-6-loaded MPs revealed important features: 
i) coumarin-6-concentration dependent saturation of the fluorescence intensity of the probe, 
particularly for coumarin-6 concentration above 0.20 g/mg (green), ii) red-shift in coumarin-6 
emission spectra when coumarin-6 concentration increases from 0.04 to 1.00 g/mg, regardless of MP 
composition and iii) decrease in the fluorescence anisotropy of coumarin-6 when MPs were loaded 
with 0.20, 0.40 and 1.00 g/mg . Overall, these results indicate an alteration in the environment where 
coumarin-6 is localized, from less polar environment within the PLGA hydrophobic matrix, to a more 
polar environment at the surface of the MPs or even in the water. Apart from the behaviors above 
described, values from F.I. MAX (Figure 5.5 A and Figure 5.7) are lower for PLGA CH-C6 MPs and 
higher for PLGA PVA-C6 MPs and PLGA ALG-C6 MPs. The referred trend strongly corroborates 
with E.E. and L.C. results. So, PLGA CH-C6 MPs demonstrated the lowest tendency to entrap 
coumarin-6. In addition, values of D50% and ZP were independent of the introduction of the probe. In 
conclusion, coumarin-6 spectral characterization demonstrated that the entrapment of the probe into 
the surface modified PLGA MPs leads to a probe/MPs stable system.  
 
6.2  Impact of surface properties of the surface modified MPs in 
interactions with GUVs 
The vesicles produced were labeled with Rho-DOPE. As Silva et al. described, the partition 
coefficient of Rho-DOPE between the lo and the ld phases in POPC/SM/Chol (1:1:1 mol/mol/mol) is 
0.28±0.08 meaning that this probe has a high affinity to fluid disordered phases (116). Rho-DOPE 
displayed homogeneous distribution along the entire POPC vesicles, as expected for vesicles formed 
by a single lipid with very low melting temperature (Tm= -2˚C, (117)), and therefore fluid at the 
temperature employed in the present study. In contrast, POPC/DPPC (1:1 mol/mol) GUVs displayed 
gel-fluid phase separation, as expected for this mixture (118). For POPC/SM/Chol (1:1:1 
mol/mol/mol) GUVs lo-ld should be presented in all GUVs produced. This is mainly evidenced by the 
presence of the dark circular domains along the vesicle. However, some vesicles displayed gel-fluid 
phase separation, as denoted by the dendritic/tubular dark regions observed. This phenomenon can be 
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Figure 6.1 PSM/POPC/Chol phase diagram at 
23 °C. experimental points are represented by 
circles (122). 
explained by some experimental errors: i) lipids stock solutions could display concentration different 
from the one assayed, ii) the lipid proportions of each component were not mixed correctly and iii) 
experimental temperature different from 23 ˚C. Overall, those experimental errors could have 
contributed to a lipid proportion different from the ideal 1:1:1 proportion (Figure 6.1, purple point at 
the phase diagram). 
GUVs produced have sizes ranging from 15 to 30 μm which is within the size range described 
for macrophage cells (119). It is well documented that these cells are able to phagocytize MPs with the 
same diameters as the ones produced in this study (4). The interactions observed for PLGA CH-C6-3 
MPs and PLGA ALG-C6-3 MPs and POPC/DPPC GUVs seemed to happen essentially at the interface 
of the fluid-gel phases. From the literature, it is known that phase separation regions trigger packing 
defects at the membrane (84). In fact, the MPs affinity to this interface region could be related with 
packing defects that may allow the MPs integration on the membrane. In addition, at this region, the 
physico-chemical properties of the membrane could be altered (87). In this region, the ZP alteration 
can be present due to lipids interaction. This phenomenon can explain the presence of negative charges 
in coexistence with positive charges that trigger electrostatic attraction of PLGA CH-C6-3 MPs and 
PLGA ALG-C6-3 MPs, respectively. Results shown strongly corroborate that the interface of the gel-
fluid phases is a preferential region for interaction of highly positive and highly negative PLGA MPs 
and GUVs.  
In physiological terms, these observations can raise some questions. How important is the 
interaction between MPs and interface fluid-gel regions? Is there some relationship between these 
biophysical phases and the presence of membrane receptors? Are these phases involved in endocytic 
processes? These are some questions that have yet to be answered and that could be addressed in 
future studies.  What is the impact of all these observations in the future development of MPs? By the 
project under study it was demonstrated that under the experimental conditions employed, highly 
negative and highly positively charged PLGA MPs presented higher interaction with membrane 
models at gel-fluid phases interface. 
 
 
 43 
 
CHAPTER 7: Conclusion 
 
The main goal of this study was to evaluate the interactions between polymeric microcarriers 
with different surface charges and GUVs with different biophysical properties. In general, this study 
was intended to give additional information fundamental for a future rational design of engineered 
nano/microsystems acting as therapeutic vectors. 
 Our studies revealed that non-fluorescent and fluorescent surface-modified PLGA MPs 
displayed median sizes ranging between 1.4±0.3 to 3.8±0.2 m and presented high size dispersity. The 
surface modification and the introduction of the probe did not change significantly the median sizes. A 
clear distinction in terms of surface charge, once changing the surface modification, was attained 
under acidic pH = 5.7. In addition, coumarin-6 did not change significantly the surface charge. The 
instability of the surface-modified MPs was mainly revelead by its i) aggregation, ii) tendency to 
collapse forming sickle-like shapes (mainly the case of coumarin-6-loaded PLGA PVA MPs and 
coumarin-6-loaded PLGA ALG MPs)  and iii) span values. 
Spectral characterization revealed that the entrapment of the fluorescent dye coumarin-6 in 
PLGA MPs leads to a probe/MP stable system. Spectral properties were analyzed by fluorescence 
spectroscopy with five different probe concentrations and five concentrations of MPs in suspension. 
Results demonstrated that coumarin-6 is essently localized in the polymeric matrix since does not 
change its partion environment when changing the concentration of MPs in suspension. At higher 
concentrations (above 0.2 g/mg), the increase of the non-encapsulated molecules localized in the 
surface of the MPs or even aqueous medium lead to a decrease of anisotropy values. 
Studies on MPs-membranes interaction by confocal microscopy showed that highly positive 
PLGA CH-C6-3 MPs and highly negative PLGA ALG-C6-3 MPs interacted with GUVs and were 
mainly attracted to the gel phases and interface of fluid-gel phases. The packing defects in interface 
regions and also the ZP alteration could account for this phenomenon. These observations will help a 
more accurate design of PLGA MPs on drug delivery applications.  
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CHAPTER 8: Future Work Perspectives 
 
As future work perspectives, the formulation method could be optimized in order to achieve 
homogeneous surface modified PLGA MPs populations (both unloaded and coumarin-6 loaded). It 
would be interesting to compare the behavior of MPs and NPs in order to study the size effect. Also, 
the ZP of the different GUVs could be measured in order to better understand the role of membrane 
charges in membrane-MP interactions. 
In microscopy studies, the experimental conditions could be further optimized. Real time 
microscopy techniques could be used in order to acquire more accurate results. In this way, using the 
same method, several dilutions of the coumarin-6 loaded surface modified PLGA NPs/MPs 
suspension could be tested. This could allow a more precise selection of the PLGA-C6 MPs/GUVs 
favorable proportion to their interaction. In addition, microscopy studies could also be performed 
under physiological pH, to further extend this study to the normal extracellular medium condition 
found in biological cells. 
Finally, at a later stage, it would be interesting to confirm the observations made using 
membrane models in more complex systems such as cellular models, using different types of cells. 
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Annexes 
Annex 1  
Excitation and emission spectra of coumarin-6 in PLGA PVA-C6-1/2/4/5 MPs, PLGA CH-C6-1/2/4/5 
MPs and PLGA ALG-C6-1/2/4/5 MPs suspensions with MPs concentrations of 0.50 mg/mL, 0.40 
mg/mL, 0.25 mg/mL, 0.20 mg/mL and 0.10 mg/mL. 
 
A 
B 
C D 
Figure A.1 Coumarin-6 excitation and emission spectra in PLGA PVA-C6 MPs labeled with 0.04, 0.1, 0.4 and 1.00 
g/mg of coumarin-6 for the different concentrations of MPs in suspension. Excitation and emission spectra of (A) 
PLGA PVA-C6-1 MPs, (B) PLGA PVA-C6-2 MPs, and (C) PLGA PVA-C6-4 MPs and (D) PLGA PVA-C6-5 MPs. 
Data for the concentrations of PLGA in suspension 0.10 mg/mL, 0.20 mg/mL, 0.25 mg/mL, 0.40 mg/mL and 0.50 
mg/mL are shown in blue, red, green, purple and light blue. Data correspond to N = 1, n = 1. Measurements were 
performed setting λem=510 nm during the acquisition of the excitation spectra and λex = 445 nm during the acquisition 
of the emission spectra. F.I. Fluorescence Intensity (a.u). 
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Figure  A.2 Coumarin-6 excitation and emission spectra in PLGA CH-C6 MPs labeled with 0.04, 0.1, 0.4 and 1.00 
g/mg of coumarin-6 for the different concentrations of MPs in suspension. Excitation and emission spectra of (A) 
PLGA CH-C6-1 MPs, (B) PLGA CH-C6-2 MPs, and (C) PLGA CH-C6-4 MPs and (D) PLGA CH-C6-5 MPs. Data 
for the concentrations of  PLGA in suspension 0.10 mg/mL, 0.20 mg/mL, 0.25 mg/mL, 0.40 mg/mL and 0.50 
mg/mL are shown in blue, red, green, purple and light blue. Data correspond to N = 1, n = 1. Measurements were 
performed setting λem=510 nm during the acquisition of the excitation spectra and λex = 445 nm during the 
acquisition of the emission spectra. F.I. Fluorescence Intensity (a.u). 
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Figure A.3 Coumarin-6 excitation and emission spectra in PLGA ALG-C6 MPs labeled with 0.04, 0.1, 0.4 and 1.00 
g/mg of coumarin-6 for the different concentrations of MPs in suspension. Excitation and emission spectra of (A) 
PLGA ALGC6-1 MPs, (B) PLGA ALG-C6-2 MPs, and (C) PLGA ALG-C6-4 MPs and (D) PLGA ALG-C6-5 MPs. 
Data for the concentrations of  PLGA in suspension 0.10 mg/mL, 0.20 mg/mL, 0.25 mg/mL, 0.40 mg/mL and 0.50 
mg/mL are shown in blue, red, green, purple and light blue. Data correspond to N = 1, n = 1. Measurements were 
performed setting λem=510 nm during the acquisition of the excitation spectra and λex = 445 nm during the acquisition 
of the emission spectra. F.I. Fluorescence Intensity (a.u). 
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Figure A.4 Coumarin-6 normalized excitation and emission spectra in PLGA PVA-C6 MPs labeled with 0.04, 
0.1, 0.4 and 1.00 g/mg of coumarin-6 for the different concentrations of MPs in suspension. Excitation and 
emission spectra of (A) PLGA PVA-C6-1 MPs, (B) PLGA PVA-C6-2 MPs, and (C) PLGA PVA-C6-4 MPs and 
(D) PLGA PVA-C6-5 MPs. Data for the concentrations of PLGA in suspension 0.10 mg/mL, 0.20 mg/mL, 0.25 
mg/mL, 0.40 mg/mL and 0.50 mg/mL are shown in blue, red, green, purple and light blue. Data correspond to N 
= 1, n = 1. Measurements were performed setting λem=510 nm during the acquisition of the excitation spectra 
and λex = 445 nm during the acquisition of the emission spectra. F.I. Fluorescence Intensity (a.u). 
A B 
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Normalized excitation and emission spectra of coumarin-6 in PLGA PVA-C6-1/2/4/5 MPs, PLGA 
CH-C6-1/2/4/5 MPs and PLGA ALG-C6-1/2/4/5 MPs suspensions with MPs concentrations of 0.50 
mg/mL, 0.40 mg/mL, 0.25 mg/mL, 0.20 mg/mL and 0.10 mg/mL. 
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Figure A.5 Coumarin-6  normalized excitation and emission spectra in PLGA CH-C6 MPs labeled with 0.04, 
0.1, 0.4 and 1.00 g/mg of coumarin-6 for the different concentrations of MPs in suspension. Excitation and 
emission spectra of (A) PLGA CH-C6-1 MPs, (B) PLGA CH-C6-2 MPs, and (C) PLGA CH-C6-4 MPs and (D) 
PLGA CH-C6-5 MPs. Data for the concentrations of PLGA in suspension 0.10 mg/mL, 0.20 mg/mL, 0.25 
mg/mL, 0.40 mg/mL and 0.50 mg/mL are shown in blue, red, green, purple and light blue. Data correspond to N 
= 1, n = 1. Measurements were performed setting λem=510 nm during the acquisition of the excitation spectra 
and λex = 445 nm during the acquisition of the emission spectra.  F.I. Fluorescence Intensity (a.u). 
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Figure A.6 Coumarin-6 normalized excitation and emission spectra in PLGA ALG -C6 MPs labeled with 0.04, 0.1, 0.4 and 1.00 g/mg 
of coumarin-6 for the different concentrations of MPs in suspension. Excitation and emission spectra of (A) PLGA ALG-C6-1 MPs, (B) 
PLGA ALG -C6-2 MPs, and (C) PLGA ALG -C6-4 MPs and (D) PLGA ALG -C6-5 MPs. Data for the concentrations of  PLGA in 
suspension 0.10 mg/mL, 0.20 mg/mL, 0.25 mg/mL, 0.40 mg/mL and 0.50 mg/mL are shown in blue, red, green, purple and light blue. 
Data correspond to N = 1, n = 1. Measurements were performed setting λem=510 nm during the acquisition of the excitation spectra and 
λex = 445 nm during the acquisition of the emission spectra. F.I. Fluorescence Intensity (a.u). 
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Figure A.7 Coumarin-6 normalized spectra in PLGA PVA-C6 MPs suspensions with concentration of MPs (A) 0.1 
g/mL, (B) 0.2 mg/mL, (C) 0.4 mg/mL and (D) 0.5 mg/mL labeled with coumarin-6 different concentrations of 
coumarin-6. Data for the concentrations of coumarin-6 0.04 g/mg, 0.1 g/mg, 0.2 g/mg, 0.4 g/mg and 1 g/mg 
are shown in blue, red, green, purple and light blue. Data correspond to N = 1, n = 1. Measurements were performed 
setting λex = 445 nm during the acquisition of the emission spectra. F.I. Fluorescence Intensity (a.u.). 
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Annex 2  
Emission spectra of PLGA PVA-C6-1/2/4/5 MPs, PLGA CH-C6-1/2/4/5 MPs and PLGA ALG-C6-
1/2/4/5 MPs suspensions with MPs concentrations of 0.50 mg/mL, 0.40 mg/mL, 0.25 mg/mL, 0.20 
mg/mL and 0.10 mg/mL.  
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Figure  A.8  Coumarin-6 normalized spectra in PLGA CH-C6 MPs suspensions with concentration of MPs (A) 0.1 
g/mL, (B) 0.2 mg/mL, (C) 0.4 mg/mL and (D) 0.5 mg/mL labeled with coumarin-6 different concentrations of 
coumarin-6. Data for the concentrations of coumarin-6 0.04 g/mg, 0.1 g/mg, 0.2 g/mg, 0.4 g/mg and 1 g/mg 
are shown in blue, red, green, purple and light blue. Data correspond to N = 1, n = 1. Measurements were performed 
setting λex = 445 nm during the acquisition of the emission spectra. F.I. Fluorescence Intensity (a.u.). 
A B 
C D 
 
 
 
 
 
 
 
 61 
 
Figure A.9 Coumarin-6 normalized spectra in PLGA ALG-C6 MPs suspensions with concentration of MPs (A) 0.1 
g/mL, (B) 0.2 mg/mL, (C) 0.4 mg/mL and (D) 0.5 mg/mL labeled with coumarin-6 different concentrations of 
coumarin-6. Data for the concentrations of coumarin-6 0.04 g/mg, 0.1 g/mg, 0.2 g/mg, 0.4 g/mg and 1 g/mg 
are shown in blue, red, green, purple and light blue. Data correspond to N = 1, n = 1. Measurements were performed 
setting λem=510 nm during the acquisition of the excitation spectra and λex = 445 nm during the acquisition of the 
emission spectra. F.I. Fluorescence Intensity (a.u.). 
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Figure A.10 Variation of em with the concentration of coumarin-6 in (A) PLGA PVA-C6 MPs, (B) PLGA CH-C6 MPs 
and (B) PLGA ALG-C6 MPs. Data for the concentrations of MPs in suspension 0.10 mg/mL, 0.20 mg/mL, 0.40 mg/mL 
and 0.50 mg/mL are shown in blue, red, green, purple and light blue. Data correspond to N = 1, n = 1. 
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Annex 3  
Variation of the em max of PLGA PVA-C6 MPs, PLGA CH-C6 MPs and PLGA ALG-C6 MPs as a 
function of concentration of coumarin-6 
 
 
